Archive for September, 2020

PHOENIX, Sept. 8, 2020 /PRNewswire/ --(OTC CELZ) -- Creative Medical Technology Holdings Inc. announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office for its patent application, "Perispinal Perfusion by Administration of T Regulatory Cells Alone or in Combination with Angiogenic Cell Therapies."

The patent covers the use of activated T regulatory cells for inducing an increase in blood circulation in areas surrounding the disc of patients with lower back pain. It is believed that a significant proportion of patients suffering from lower back pain have abnormally poor circulation, which does not effectively remove waste products and irritants. Restoration of circulation in the lower back is associated with reduction of pain.

The Company acquired a previously granted US Patent # 9,598,673 covering use of various types of stem cells, autologous and allogeneic, for treating lower back pain. The Company has completed an autologous cell therapy pilot study in the area of lower back pain utilizing this patented technology and is currently in the process of assembling data for publication.

"Creative Medical Technology Holdings is developing a critical mass of issued intellectual property covering multiple cell therapy treatments of lower back pain as well as other indications," said Timothy Warbington, President and CEO of the Company. "Testimony to the size of the lower back pain market is the $1 Billion Mesoblast-Grunenthal deal for a pre-review cell therapy product1. We are enthusiastic to add this new therapy to our expanding portfolio of rapid-to-commercialize cellular therapies."

Creative Medical Technology Holdings has previously commercialized its CaverStemR technology involving personalized bone marrow cellular therapy for erectile dysfunction. This technology is covered by issued patent # 8,372,797 and a clinical trial demonstrating safety with signals of efficacy published in the peer-reviewed literature2.

"Immunotherapy is one segment of the biotechnology industry that is expanding at an exponential rate," said Donald Dickerson, CFO of the Company. "The recent Nobel Prize in the area of Immunotherapy of Cancer, as well as the current valuations of immunotherapy companies, validates the approaches that we have been developing, and now patenting. Essentially our approach is to use stem cells, or immunotherapy to enable the body to heal itself."

"The Company welcomes the biotechnology/life sciences community and key opinion leaders to contact us to discuss potential collaboration on our patented technologies in this amazing space," Mr. Warbington said further.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visit http://www.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at http://www.sec.gov.

Creativemedicaltechnology.comwww.StemSpine.com http://www.Caverstem.com http://www.Femcelz.com

1 https://www.biopharma-reporter.com/Article/2019/09/12/Gruenenthal-partners-with-Mesoblast-for-back-pain-cell-therapy#:~:text=Gr%C3%BCnenthal%20agrees%20deal%20with%20Mesoblast,disease%20in%20previously%20treated%20patients.

2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958721/

SOURCE Creative Medical Technology Holdings, Inc.

Home

Read more:
Application of Immunotherapy to $7 Billion Lower Back Pain Market Patented by Creative Medical Technology Holdings - PRNewswire

Hematopoietic stem cells are young or immature blood cells found to be living in bone marrow. These blood cells on mature in bone marrow and only a small number of these cells get to enter blood stream. These cells that enter blood stream are called as peripheral blood stems cells. Hematopoietic stem cells transplantation is replacement of absent, diseased or damaged hematopoietic stem cells due to chemotherapy or radiation, with healthy hematopoietic stem cells. Over last 30 years hematopoietic stem cells transplantation market seen rapid expansion and constant expansion with lifesaving technological advances. Hematopoietic stem cells transplantation is also known blood and marrow transplantation which brings about reestablishment of the patients immune and medullary function while treating varied range of about 70 hematological and non-hematological disorders. In general hematopoietic stem cells transplantation is used in treatment of hereditary, oncological, immunological and malignant and non-malignant hematological diseases.

There are two types of peripheral blood stem cell transplants mainly autologous and allogeneic transplantation. In autologous transplants patients own hematopoietic stem cells are harvested or removed before the high-dose treatment that might destroy the patients hematopoietic stem cells. While in allogeneic transplants stem cells are obtained from a tissue type of matched or mismatched donor. Hematopoietic stem cells are harvested from blood or bone marrow and is then frozen to use later. Depending upon the source of hematopoietic stem cells, worldwide there are three types of hematopoietic stem cells transplants namely bone marrow transplant (BMT), peripheral blood stem cell transplant and cord blood transplant. Major drivers in the hematopoietic stem cells transplantation market are establishment of strong and well developed network of hematopoietic stem cells transplantation organizations having global reach and presence has recognized NGO named Worldwide Network for Blood and Marrow Transplantation Group (WBMT) in official relation with World Health Organization (WHO) and rapid increase in number of transplants. Major restraints in hematopoietic stem cells transplantation market is high cost of transplantation and lack of funding for WBMT and other organizations such as regional, national and donor.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/14563

The global market for Hematopoietic stem cells transplantation market is segmented on basis of transplant type, application, disease indication, end user and geography:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/14563

Based on transplantation type, hematopoietic stem cells transplantation market is segmented into allogeneic and autologous. Hematopoietic stem cells transplantation market is also segmented by application type into bone marrow transplant (BMT), peripheral blood stem cell transplant and cord blood transplant. The market for hematopoietic stem cells transplantation is majorly driven by bone marrow transplant (BMT) segment. Based on end user hematopoietic stem cells transplantation market is segmented into hospitals and specialty centers. Peripheral blood stem cell transplant type holds the largest market for hematopoietic stem cells transplantation. Hematopoietic stem cells transplantation market is further segmented by disease indication into three main categories i.e. lymphoproliferative disorders, leukemia, and non-malignant disorders. Segment lymphoproliferative disorder holds largest share amongst the three in Hematopoietic stem cells transplantation market. On the basis of regional presence, global hematopoietic stem cells transplantation market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Europe leads the global hematopoietic stem cells transplantation market followed by U.S. due to easy technological applications, funding and high income populations. Other reasons for rise in hematopoietic stem cells transplantation market is high prevalence of lymphoproliferative disorders and leukemia; demand for better treatment options; and easy accessibility and acceptance of population to new technological advances. Transplantation rates in high income countries are increasing at a greater extent but continued rise is also seen in low income countries and expected to rise more. Hematopoietic stem cells transplantation market will have its potential in near future as being a perfect alternative to traditional system in many congenital and acquired hematopoietic disorders management. While India, China and Japan will be emerging as potential markets. An excellent and long term alternative to relief by side effects of chemotherapy, radiotherapy and immune-sensitive malignancies is another driver for hematopoietic stem cells transplantation market. The key players in global hematopoietic stem cells transplantation market are Lonza, Escape Therapeutics, Cesca Therapeutics Inc., Regen BioPharma, Inc., Invitrx Inc, StemGenex, Lion Biotechnologies, Inc., CellGenix GmbH, Actinium Pharmaceuticals, Inc., Pluristem, Kite Pharma, Novartis AG.You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/14563

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Continue reading here:
Global Hematopoietic Stem Cells Transplantation Market to Witness Rapid Development During the Period 2017 2025 - The News Brok

A novel Bcl-2 inhibitor, APG-2575, has been granted an Orphan Drug designation (ODD) by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL), announced Ascentage Pharma in a press release.1

This marks the second ODD for APG-2575, after 1 was granted to the drug in July 2020 for the treatment of Waldenstrm Macroglobulinemia (WM).2

At present, CLL still presents considerable unmet medical needs. APG-2575 is a key drug candidate in Ascentage Pharma's pipeline targeting apoptosis. The APG-2575 received this ODD from the FDA shortly after the first ODD in WM, and this designation will be helpful in enhancing our communication with the FDA and expediting our development of APG-2575 in these rare cancer diseases," said Yifan Zhai, MD, PhD, chief medical officer, Ascentage Pharma, in a statement.1 All the policy support and incentives as a result of this ODD will help us accelerate the global clinical development of APG-2575, which we hope will soon offer additional treatment options for patients with CLL."

In hematologic malignancies, APG-2575 may selectively block Bcl-2 as a way to renew the apoptosis process in cancer cells. The first study of APG-2575 in CLL, as well as in small lymphocytic leukemia (SLL), is currently recruiting 35 patients with relapsed or refractory disease. In the phase 1b dose-escalation study (NCT04215809), patients will receive APG-2575 alone or in combination with other therapeutic agents. The primary end point of the study is dose-limiting toxicity, and the secondary end point is the maximum tolerated dose of APG-2575.

The study will follow a non-randomized 3 + 3 design at a starting dose of 200 mg given on day 1 of a 28-day cycle. The dose will be increased to 400 mg, followed by 600 mg, 800 mg, and 1200 mg.

To be included in the trial, patients must be 18 years or older with a histologically confirmed diagnosis of CLL/SLL, and ECOG performance status of 2 or lower, adequate bone marrow function, and a serum creatinine level of 1.5upper limit of normal. In part 1, patients will be eligible for dose escalation if they have received 3 or fewer prior lines of systemic therapy. Female patients are required to be postmenopausal for 2 years or surgically sterile prior to beginning treatment in the study.

Patients are excluded from this study if they have undergone allogeneic stem cell transplant within 90 days of joining the study, have active graft-versus-host-disease or are in need of immunosuppressive therapy, and/or have Richter's syndrome. The study also excludes patients with certain prior therapies and comorbidities that may interfere with APG-2575 treatment.

Multiple cancer centers in the United States are involved in the phase 1b study of APG-2575 including the Mayo Clinic in Scottsdale Arizona, City of Hope in Duarte, California, Dana-Farber Cancer Institute in Boston, Massachusetts, Novant Health in Charlotte, North Carolina, Grabrail Cancer Center in Canton, Ohio, Cleveland Clinic in Cleveland, Ohio, and Swedish Health in Seattle, Washington.

Outside of the realm CLL/SLL, APG-2575 is being investigated in other hematologic malignancies like WM, AML, and T-cell prolymphocytic leukemia. Studies of APG-2575 in these disease states are currently recruiting patients in centers in the United States, Australia, and China.

References:

1. Ascentage Pharma's Bcl-2 inhibitor apg-2575 granted Orphan Drug designation by the FDA for the treatment of chronic lymphocytic leukemia. News release. Ascentage Pharmaceuticals. September 7, 2020. Accessed September 8, 2020. https://prn.to/2ZiOqFJ

2. Ascentage Pharmas Bcl-2 inhibitor apg-2575 granted Orphan Drug Designation by the FDA for the treatment of waldenstrm macroglobulinemia. News release. Ascentage Pharmaceuticals. July 15, 2020. Accessed September 8, 2020. https://bit.ly/329A5gL

Excerpt from:
FDA Grants Orphan Drug Designation to Novel Bcl-2 inhibitor in CLL - Targeted Oncology

Skin fibroblasts were successfully reprogrammed into the smooth muscle cells (red) and endothelial cells (white) which surround blood vessels. The cells nuclei are shown in blue. Credit: Bersini, Schulte et al. CC by 4.0

Salk study is the first to reveal ways cells from the human circulatory system change with age and age-related diseases.

Salk scientists have used skin cells called fibroblasts from young and old patients to successfully create blood vessels cells that retain their molecular markers of age. The teams approach, described in the journal eLife on September 8, 2020, revealed clues as to why blood vessels tend to become leaky and hardened with aging, and lets researchers identify new molecular targets to potentially slow aging in vascular cells.

The vasculature is extremely important for aging but its impact has been underestimated because it has been difficult to study how these cells age, says Martin Hetzer, the papers senior author and Salks vice president and chief science officer.

Research into aging vasculature has been hampered by the fact that collecting blood vessel cells from patients is invasive, but when blood vessel cells are created from special stem cells called induced pluripotent stem cells, age-related molecular changes are wiped clean. So, most knowledge about how blood vessel cells age comes from observations of how the blood vessels themselves change over time: veins and arteries become less elastic, thickening and stiffening. These changes can contribute to blood pressure increases and a heightened risk of heart disease with age.

From left: Martin Hetzer and Simone Bersini. Credit: Salk Institute

In 2015, Hetzer was part of the team led by Salk President Rusty Gage to show that fibroblasts could be directly reprogrammed into neurons, skipping the induced pluripotent stem cell stage that erased the cells aging signatures. The resulting brain cells retained their markers of age, letting researchers study how neurons change with age.

In the new work, Hetzer and his colleagues applied the same direct-conversion approach to create two types of vasculature cells: vascular endothelial cells, which make up the inner lining of blood vessels, and the smooth muscle cells that surround these endothelial cells.

We are among the first to use this technique to study the aging of the vascular system, says Roberta Schulte, the Hetzer lab coordinator and co-first author of the paper. The idea of developing both of these cell types from fibroblasts was out there, but we tweaked the techniques to suit our needs.

The researchers used skin cells collected from three young donors, aged 19 to 30 years old, three older donors, 62 to 87 years old, and 8 patients with Hutchinson-Gilford progeria syndrome (HGPS), a disorder of accelerated, premature aging often used to study aging.

The resulting induced vascular endothelial cells (iVECs) and induced smooth muscle cells (iSMCs) showed clear signatures of age. 21 genes were expressed at different levels in the iSMCs from old and young people, including genes related to the calcification of blood vessels. 9 genes were expressed differently according to age in the iVECs, including genes related to inflammation. In patients with HGPS, some genes reflected the same expression patterns usually seen in older people, while other patterns were unique. In particular, levels of BMP-4 protein, which is known to play a role in the calcification of blood vessel, were slightly higher in aged cells compared to younger cells, but more significantly higher in smooth muscle cells from progeria patients. This suggests that the protein is particularly important in accelerated aging.

The results not only hinted at how and why blood vessels change with age, but confirmed that the direct-conversion method of creating vascular endothelial and smooth muscle cells from patient fibroblasts allowed the cells to retain any age-related changes.

One of the biggest theoretical implications of this study is that we now know we can longitudinally study a single patient during aging or during the course of a treatment and study how their vasculature is changing and how we might be able to target that, says Simone Bersini, a Salk postdoctoral fellow and co-first author of the paper.

To test the utility of the new observations, the researchers tested whether blocking BMP4 which had been present at higher levels in smooth muscle cells developed from people with HGPS could help treat aging blood vessels. In smooth muscle cells from donors with vascular disease, antibodies blocking BMP4 lowered levels of vascular leakiness one of the changes that occurs in vessels with aging.

The findings point toward new therapeutic targets for treating both progeria and the normal age-related changes that can occur in the human vascular system. They also illustrate that the direct conversion of fibroblasts to other mature cell types previously successful in neurons and, now, in vascular cells is likely useful for studying a wide range of aging processes in the body.

By repeating what was done with neurons, weve demonstrated that this direct reprogramming is a powerful tool that can likely be applied to many cell types to study aging mechanisms in all sorts of other human tissues, says Hetzer, holder of the Jesse and Caryl Philips Foundation Chair.

The team is planning future studies to probe the exact molecular mechanisms by which some of the genes they found to change with age control the changes seen in the vasculature.

Reference: Direct reprogramming of human smooth muscle and vascular endothelial cells reveals defects associated with aging and Hutchinson-Gilford progeria syndrome by Simone Bersini, Roberta Schulte, Ling Huang, Hannah Tsai and Martin W Hetzer, 8 September 2020, eLife.DOI: 10.7554/eLife.54383

Other researchers on the study were Ling Huang and Hannah Tsai of Salk. The work was supported by grants from the National Institutes of Health, the NOMIS Foundation and an AHA-Allen Initiative in Brain Health and Cognitive Impairment award made jointly through the American Heart Association and the Paul G. Allen Frontiers Group. Simone Bersini was supported by the Paul F. Glenn Center for Biology of Aging Research at the Salk Institute.

See the article here:
Scientists May Have Discovered a Way to to Slow Aging by Direct Reprogramming of Human Cells - SciTechDaily

Im not saying my skin has aged significantly this year but my six-year-old recently asked me why I had asix-pack on my forehead. After six months of stressful days, sleepless nights and home-school nightmares, its become apparent that matters need taking in hand. And theres something about the early autumn, with its nip in the air, and its new-found appreciation for proper, non-negotiable routines that feels right for a skincare overhaul.

Fortunately, the seasons big skincare launches abound with new ways to reset your skin, from serious, sleeves-rolled-up jump-starting regimens, which last up to a month and deliver a rapid burst of intense reconditioning, to new strategies that claim todetoxify your daily regime without your having to somuch as cut down on caffeine.

Sorting out most modern-day skincare complaints from sluggish cell turnover caused by tiredness and stress to overstimulated skin (a result of using products not suited to one another), to undeserved lacklustre complexions caused by outdated products requires a bit of areboot. It could be a facial; it could be a peel. But inthedays when weve all become beauty hobbyists, performing DIY facials like pros, it could also be a pleasurable at-home experience for the price of a couple ofdecent salon treatments.

Dr Anita Sturnham, a London-based GP specialising in dermatology who launched her own excellent skincare line,Decree, last year, became so aware of how many of herpatients especially those suffering with breakouts, pigmentation and dehydration needed a thorough overhaul that she recently launched her own two-week Skin Reset Kit. Sturnham believes 90 per cent of the skin issues she sees are self-inflicted simply by using the wrong products and that stripping your skincare right back is an essential step for getting the best from your skin.

Another recent reset kit is Budapest brand Omoroviczas The Cure programme, which in nine days cycles through anacid phase (to resurface), a remineralise phase (tostimulate microcirculation) and a reconstruct phase (forrenewed elasticity). You can repeat it every three months, ideally to coincide with the change of seasons.

One of the best known brands for an intensive treatment is that of anthropologist-turned-dermatologist Dr Phillip Levy. A Geneva-based wound-healing specialist,he believes that only via resetting can you achieve some of the most visible anti-ageing results andhis Ultimate Stem Cell Spring Homecure (the springmeans spring clean but it can bestarted any time)is legendary. Manyofthe cures we have studied over the years seem to be everyday products nicely repackaged, he says.But to have something truly transformational, theyneed go deep enough to stimulate your own collagen, elastin and hyaluronic acid production, and last four weeks or even eight or more.

Its true that these regimes work best when they feel elevated from the everyday. And when it comes to products with a built-in sense of occasion, no one does it better than Sisley. Even before you get to the science and the scents, and the textures it has a particular French earnestness that makes every product feel like an event. Which must make LIntgral Anti-Age La Cure, its new skin-resetting regimen, at 775 for a four-week supply, a veritable tapis rouge.

For each of the four week-long phases Impulse, Reset, Consolidate, Renaissance theres a phial of creamy serum, about the size of an eye cream. You use each one for seven days, applying eight pumps of product morning and night (this feels a lot, and it takes a few minutes to properly sink in). You can follow with eye cream or moisturiser if you want to, but I didnt feel the need. The bottles have been slightly overfilled so as to ensure you dont run out, but when you get to the end of the seventh day, you must start the next one nonetheless. (This feels wasteful, but I was assured by Sisleys training manager Lorna Green that I could save up these last drops and use them a couple of weeks after the course, as a further boost).

The formulation works on the skins mitochondria the batteries where cellular energy is stored. Theylose the ability to restore themselves over time, particularly during intense periods of stress and hormonal changes, so following either one of those would be an ideal time to try it. The breakthrough wasthe discovery of the mechanisms of a process called autophagy (for which Japanese biologist Yoshinori Ohsumi won the Nobel Prize for medicine in2016), whereby damaged cell components such as mitochondria destroy themselves to protect the rest ofthe cell. La Cure boosts the elimination of these wasteelements, allowing the healthy cells left behind tosoak up energy and regenerate promoting the appearanceof healthier, more youthful skin. In skincare terms, this is no mean feat.

Where the real technology is happening, it wont be long before they eclipse the big jars of moisturiser completely

It sounds intense and its certainly super-active: by the end of the first week I had a small, yet determined, spot on my chin (which I cannot believe was a coincidence) and a little more redness than usual, too. The following week, cell detoxification week, my skin was starting to feel unusually smooth. By the end of the fourth week, my skin was smoother and clearer than I can ever remember. Its also, though, a real example of skincare as self-care: as much as the thought of a radically rejuvenated complexion, the daily reminder that youve sidelined your usual clutter of products in favour of something exceptional is almost enough to bring on a glow.

With any reset complete, the focus should then be on keeping your skin detoxified and renewed. One update worth looking at is a serum. Whereas the luxurious facecream at the end of your regime used to be the jewel in any skincare crown, these dayslightweight serums are where the real technology ishappening, and it wont be long before they eclipse thebig jars of moisturiser completely.

While serums used to be a targeted addition to your face cream specifically for age spots, say, or wrinkles the best new ones are genuinely impressive all-rounders. Este Lauder has just revamped Advanced Night Repair, one of the first ever mainstream skin serums and a product so ubiquitous that among beauty editors it has acronym status. (See also: Cliniques DDML, aka Dramatically Different Moisturizing Lotion). And in October, Suqqu, which hails from Japan where serums have been the mainstay of skincare much longer than here will launch Vialume, its most advanced line yet, containing glucosamine and amino-acid derivatives designed to targetall five key characteristics of great skin: moisture, firmness, smoothness, translucency and brightness.

Another product gaining increasingly scientific status is face oil, which should no longer be dismissed as the preserve of the militantly natural beauty brigade. Augustinus Bader, the world-leading wound-healing specialist whose Rich Cream was the runaway skincare success of 2018, has just launched The Face Oil, which contains a slew of delicious-sounding oils argan, babassu, hazelnut, karanja as wellas a healthy dose of TFC8, the complex of vitamins, amino acids and synthesised molecules that has made Baders products famous. Meanwhile, RVive Glow Elixir Hydrating Radiance Oil is bronze in colour and slightly shimmering although unusually, it leaves no evidence of glittery particles. Alongside a cocktail of seed oils, it contains the brands signature Bio-Renewal Protein, rendering it a real skincare/make-up hybrid and a great transitional product for this time of year.

Another need-to-know and a great option particularly for younger skin is Rihannas new Fenty Skin line. Theres Total Cleansr, which would work especially well as the first step of a double-cleanse, and Fat Water, which Ri-Ri calls a toner-serum hybrid but its the Hydra Vizor daily moisturiser that triumphs. This so-called Invisible Moisturizer has an SPF30 that leaves no white cast to the skin whatsoever, primarily because the product has a gorgeous pinkish hue and a blurring effect. The ghostly pallor left behind by so many SPF products is a particular challenge to people of colour and this range was designed to work seamlessly with make-up on all skin tones. It also smells great juicy with just the slightest medicinal tinge and comes in a refillable tube.

The recently launched skincare brand U Beauty wants to reset not just your skin, but the way you think about your whole regime. Were all doing too much, says founder Tina Craig, who until two years ago was working as an influencer/ambassador for the worlds biggest skincare brands but admits being as confused as anyone about what to use; she had ended up with a 13-step skincare routine. I started noticing that everyone Iknew had skin that looked translucent, which is not how it should look, she says. Then I looked at my grandma and relatives in Asia, and their skin was not like that. It was thick. Dense. Firm.

U Beauty is her answer to what she calls the cosmeticconfusion. Its first product, the Resurfacing Compound (which sold out three times on UK stockist Net-aPorter), was designed to replace toner, vitamin C, hyaluronicacid, AHAs, physical exfoliants, antioxidant serums and retinol products. From this month, theres alsoSuper Smart Hydrator, a moisturising serum that seeks out damaged cells and only treats the skin where itneeds it. Bookend these two with cleanser and SPF, saysCraig, and youre good to go.

Finally, could we reset the way we use products altogether? New brand Noble Panacea is overseenby ascientific heavyweight: Sir Fraser Stoddart, who was awarded the 2016 Nobel Prize in chemistry. A microscopic delivery system releases its active ingredients into the skinin a programmed sequence, and it comes in individualdoses packed in mini sachets to ensure the optimal amount of these ingredients stays potent until theminute it reaches your skin.

On the one hand, they feel counter to the idea of luxury face creams more like a free sample from a beauty hall but on the other, the boxes made from renewable materials and ultra-hygienic 0.5ml doses feel modern and Covid-safe. (You can send them for recyling in a complimentary envelope to TerraCycle, with which the brand has partnered). And if nothing else, as its global ambassador ithas snapped up the actress Jodie Comer, who must havebeen pursued by every beauty company under the sun and as far as I can tell, theres no sign of a six-pack on her forehead.

Read the original here:
The great beauty reset: how to reboot your skin - Financial Times

The one thing all beauty therapists should know about exfoliatingWhen were young, our cells typically take 28 days to complete the cell turnover cycle. This begins in the lowest layer of the epidermis the stratum germinativum where the stem cells are housed. From here the skin cells migrate through each layer of the epidermis until they reach the outermost layer the stratum corneum.

This process takes about 14 days, after which the cells stay in the stratum corneum for approximately another 14 days for a 28 day total cycle. At this point, the skin begins to slough off these dead skin cells, which will be replaced by new ones a process known as desquamation.

As we age, the desquamation cycle naturally slows down and leaves us with a build-up of dull, dry and dehydrated cells. Exfoliation helps speed up desquamation, making it an essential part of every clients skin care regimen.

Chemical and physical exfoliants both remove the dulling, dead skin cells that accumulate on skins surface, revealing brighter, fresher-looking skin. Regular exfoliation can also help stimulate skin cell renewal, encouraging the cells to come to skins surface more quickly.

Additionally, removing dead cells serves to increase the penetration of hydrating ingredients and other targeted treatments.

While this is common knowledge among beauty therapists, clients are often unaware of this benefit. For example, if youve ever heard a client say that their skincare products arent working anymore, its likely that a build-up of dead skin cells is preventing active ingredients from being absorbed and acting effectively on the skin. The solution: regular exfoliation.

If your clients suffer with dull, flaky skin, dryness or dehydration, then you may reach for a hydrating masque in treatment to remedy these symptoms, but if you havent exfoliated first, then dead cell build-up can act as a barrier, stopping hydrating ingredients from being effectively absorbed.

The quickest way to smooth and renew your skin is with an exfoliant. However, did you know that its critical to replenish lost moisture in the barrier within 60 seconds after exfoliating or skin will become dehydrated? WithDermalogicas Hydro Masque Exfoliantyou dont need to worry about applying two separate formulas as it combines both regimen steps in one.

DermalogicasHydro Masque Exfoliantisa hydrating and exfoliating five-minute masque that smooths and renews for healthy looking skinand offers a personalised way to exfoliate via unique touch-activated bamboo spheres.

The spheres can be moved to the areas you think clients need more exfoliation where the skin is drier or rougher in texture. The ultra-fine bamboo filled spheres dissolve upon application of light pressure, delivering a gentle level of physical exfoliation. The spheres also contain a hydrating polysaccharide and glycerin to protect the skins moisture barrier, usually depleted by exfoliating. This allows a customised exfoliating experience in contrast to dual action formulas that have no isolation of the exfoliating actives.

Another unique aspect ofthe product isthat it delivers instant and long-lasting hydration immediately as you exfoliate. The hydro-cream base of the masque contains lots of hydrating ingredients to deliver moisture and barrier restoring properties.

Snow mushroom holds 450 times its weight in water, infusing skin with hydration, and it is also rich in antioxidants and Vitamin D. The masque also contains jojoba ester and amino acids derived from sugar beets to hydrate and strengthen the skins natural barrier, with cucumber extract providing a soothing, refreshing finish.

In clinical studies,Hydro Masque Exfoliantis proven to give a smoother feeling and more hydrated skin after just one use, with 80% of consumers saying their skin felt smoother and they liked the appearance of their skin.

Exfoliation is an important regimen step for healthier, more luminous skin, just dont forget to hydrate too.

Sponsored story

Visit link:
The one thing all beauty therapists should know about exfoliating - Professional Beauty

As we move into spring, the seasonal change and being indoors more often can leave our skin feeling a little lacklustre.

If you've also got uneven skin tone, you might find yourself reaching for vitamin C products to bring that long-lost glow back to your skin. (I know I have.)

Yep, you know what I mean - dull spots or patches that make an unwelcome visit on your face. Somuch fun.

You've probably seen a few skincare ranges with vitamin C as a key ingredient, but some have harsh and unnatural chemicals too. In fact, slathering harsh chemicals on your face to try achieve a more radiant, even complexion can do more harm than good if you're not exactly sure what you're putting onto your skin.

That's why Andalou Naturals' Brightening range is the perfect example of a high-performance cult natural skincare range that addresses concerns like uneven skin tone and pigmentation, all while using potent, vitamin C-rich ingredients that pack some serious punch. Oh, it's cruelty-free too.

Andalou Clementine + C Illuminating Toner. Image: Supplied

According to a recent trial*, 86 per cent of people saw a more radiant and luminous complexion, while 73 per cent saw a more even skin tone and reduced pigmentation in 28 days when using Andalou's Brightening Range.

It's been so high in demand that the famous Brightening Pumpkin Honey Glycolic Face Mask, which Mamamia reviewed back in April, recently sold out on their website(it's back now, thankfully). While they can't make their pumpkins grow any faster, if you can't get it online you can also get it from your local Chemist Warehouse or Priceline.

You've probably seen the Andalou's Brightening Range popping up on your Instagram, with model Natalia Kalinowski, author and lifestlye influencer Sjana Elise Earp, and model and lifestyle influencer Ruby Tuesday Matthews, all singing its praises.

See the article here:
Got uneven skin tone? There's a cult natural range with vitamin C that's changing the game. - Mamamia

Medical skin care products are used for beautifying or to address some other skin care problems. The cosmetic industry is booming and skin care forms a very huge part of this industry. The aesthetic appearance is so important that people spend a lot on skin care products and treatment. People being more technologically aware of the various new skin care products trending in the market. In addition to the aesthetic application, the medical skin care products are also used to address issues such as acne, pimples or scars.

Medical Skin Care Products Market: Drivers and Restraints

The medical skin care products is primarily driven by the need of natural based active ingredients products which are now trending in the market. Consumers demand medical skin care products which favor health and environment. Moreover, the consumers are updated with the trends so that various companies end up providing such products to satisfy the customers. For instance, a single product face mask has thousands of different variants. This offers consumers different options to select the product depending on the skin type. Moreover, the market players catering to the medical skin care products are offering products with advanced technologies. For instance, Santinov launched the CICABEL mask using stem cell material based on advanced technologies. The stem cells used in the skin care product helps to to protect and activate the cells and promote the proliferation of skin epidermal cells and the anagenesis of skin fibrosis.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/18469

Medical Skin Care Products Market: Segmentation

On the basis of product type the medical skin care products market can be segmented as:

On the basis of application, the medical skin care products market can be segment as:

On the basis of distribution channel, the medical skin care products market can be segment as:

Medical Skin Care Products Market: Overview

Medical skin care products are used to address basic skin problems ranging from acne to scars. There are various advancements in the ingredients used to offer skin care products to the consumers. For instance, the use of hyaluronic acid and retinoids is the latest development in the industry. The anti-aging creams are at the forefront as the help treating issues such as wrinkles, scars, acne, and sun damage. Another, product in demand is the probiotic skincare which include lactobacillus and bifidobacterium.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/18469

Medical Skin Care Products Market: Region-wise Outlook

In terms of geography, medical skin care products market has been divided into five regions including North- America, Asia- Pacific, Middle-East & Africa, Latin America and Europe. North America dominated the global medical skin care products market as international players are acquiring domestic companies to make their hold strong in the U.S. LOral is accelerating its U.S. market by signing a definitive agreement with Valeant Pharmaceuticals International Inc. to acquire CeraVe, AcneFree and Ambi skin-care brands for US$ 1.3 billion. The acquisition is expected LOreal to get hold of the brands in the price-accessible segment. Asia Pacific is expected to be the fastest growing region owing to the increasing disposable income and rising awareness towards the skin care products.

Medical Skin Care Products Market: Key Market Participants

Some of the medical skin care products market participants are Avon Products Inc., Beiersdorf AG, Colgate-Palmolive Company, Kao Corporation, LOral S.A., Procter & Gamble, Shiseido Company, The Estee Lauder Companies Inc., Unilever PLC, Revlon, Clinique Laboratories, llc., Murad, LLC., SkinCeuticals, RMS Beauty, J.R. Watkins and 100% PURE.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/18469

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more:
Demand for Medical Skin Care Products Market to Witness Rapid Surge During the Period 2017 2025 - The News Brok

Ultas 21 Days of Beauty sale is in full swing, which means for the next couple of weeks, you can save 50% off a selection of bestselling skincare and must-have makeup. What better reason to refresh your beauty collection?

The biannual event began on Sunday, August 30, and runs through Saturday, September 19, and the daily deals include a number of of celebrity favorites from Kylie Cosmetics, Skyn Iceland, Benefit and Anastasia Beverly Hills, to name but a few.

Below, the A-list-approved beauty deals that are definitely worth your dollars.

Date: Tuesday, September 8

Loved by Gwyneth Paltrow whose partnered with Juice Beauty in 2016 to launch Goops own skincare line this vegan and cruelty-free cream is made with a proprietary blend of fruit stem cells and vitamin C infused into a resveratrol-rich grape formula. The lines booster serum will be half-off on September 8 as well.

$35 (usually $70)

Date: Thursday, September 10

I love a good summer tan, but the sun can be so damaging to your skin, Kim Kardashian wrote on her namesake app in 2018. I always wear SPF to protect my skin, but I also like to use self-tanners as safe alternative to tanning outside. She named this lightweight product as her formula of choice.

$22 (usually $44)

Date: Saturday, September 12

Speaking of the Kardashian-Jenners, you wont want to miss the chance to stock up on beauty mogul Kylies bestselling lip kits for a steal. Not a fan of the matte finish? The companys velvet version will also be half-off on September 12.

$14.50 (usually $29)

Date: Saturday, September 12

Kylie Jenner, Lili Reinhart, Bella Hadid and Rosie Huntington-Whiteley are just a few of the many celebs who love this brands signature pink drying lotion. Snag a travel-friendly version of the blemish-busting solution in this kit, along with Badescus equally popular rosewater facial spray.

$11 (usually $22)

Date: Sunday, September 13

Goldie Hawn, Kristen Bell and Julia Louis-Dreyfus cant get enough of these patches, which boast cooling and de-puffing powers. A travel-sized box with four pairs instead of the usual eight will also be half-off on September 13.

$16 (usually $32)

Date: Tuesday, September 15

This brands cult favorite Good Genes All-In-One Lactic Acid Treatment revitalizes the look of dull, congested and sun-damaged skin and comes approved by Jourdan Dunn and Helen Mirren. This handy kit includes a mini size, along with one of Sunday Rileys popular Ceramic Slip Cleanser to round out your skincare routine.

$12.50 (usually $25)

Date: Friday, September 18

Available in a range of shades, this bronzers beloved by the likes of Julianne Hough, Selena Gomez and Ariana Grande.

$15 (usually $30)

Date: Friday, September 18

Anastasia Soare is the eyebrow whisperer behind the flawless arches of stars including Kim Kardashian, Jennifer Lopez, Victoria Beckham and Amal Clooney, to name just a few. This kit comes with mini sizes of everything you need to maintain your brows at home, from Soares smash-hit Brow Wiz pencil to her Dipbrow taming gel.

$19 (usually $38)

Read the original post:
Ulta's 21 Days of Beauty sale is full of celebrity-loved makeup and skincare - Page Six

We love these products, and we hope you do too. E! has affiliate relationships, so we may get a small share of the revenue from your purchases. Items are sold by the retailer, not E!.

It's time for the shopping event skincare fanatics and makeup addicts have been waiting for:Ulta Beauty's 21 Days of Beauty is here!

From now until Saturday, September 19th, shoppers can stock up on an array of makeup and skincare products at up to 50% off. You can expect amazing buys from brands such asUrban Decay,Mario Badescu,KKW Beauty,Kylie Cosmeticsand many more! And if you're not sure about what you're buying, try before you buy with GLAMlab, Ulta Beauty's virtual product try-on (it's free on the brand's app). Just remember: you only have one day to shop each deal, so if you spot something you can't live without, make sure you grab it before it's gone!

For today's deal, you can get 50% off select faux mink lashesand 50% off Juice Beauty's Anti-Wrinkle Moisturizer and Booster Serum! Check out our faves below!

View original post here:
Ulta Beautys 21 Days of Beauty Deal of the Day: 50% Off Juice Beauty and Select Faux Mink Lashes! - E! NEWS

Well, weve made it more than halfway through the yearcan you believe it? Schools are once again starting up (online and in-person), the weather is crisper (and drier), election season is in full throttle (register to vote!), and the global pandemic continues to ravage (please wear a mask!). As we begin to settle into September, its more important than ever to take care of our bodies and minds so we can show up at full capacity for ourselves in the present. Take a moment and check-in with yourself today, whether its with a calming, immune-boosting coffee mix-in or a CBD-infused bath soak. Wake me up when September (and 2020) ends!

1. African Botanics Revitalizing Therapy GelHunched over your laptop all day? Aside from investing in a laptop stand, utilize this invigorating gel from South African-made, eco-luxury skincare brand African Botanics to soothe neck and shoulder aches. This miracle-in-a-chic-tube promises to reduce swelling, promote circulation, and provide a cooling, thermal feeling so you can restore muscles for the next workday.

2. Clevr Golden SuperLatteCancel the caffeine jitters and opt for a turmeric-and-oat-milk latte. Naturally sweetened with monk fruit and chock-full of warming spices, this Clevr spin on trendy golden milk lattes hits the spot for a comforting, post-lunch pick-me-up.

3. OUAI Chill PillsIts Friday night and youre not going anywhere, so whats there to do? Light some candles, play some jazz, draw a hot bath, and drop in these adorable OUAI Chill Pills for some seriously luxurious me-time. Each jasmine-and-rose-scented vegan tablet is filled with hemp, jojoba, and safflower seed oil to leave skin ultra moisturized.

4. Apothkary Chill The F* Out Herbal SupplementAs fall seeps in and we get closer to peppermint mocha season, this stress-reducing, serotonin-boosting elixir from Apothkary tastes like a peppermint hot chocolate mix. While we reminisce of the snowy holidays ahead, two powerhouse adaptogensreishi and ashwagandhawork wonders to relieve our pent-up anxiety.

5. Shanti Rejuvenate Roll On With Hemp CBDAyurvedic essential oils and Colorado-sourced hemp blend seamlessly to bring clarity to stressed-out brains in this Shanti Wellness roll-on. The small, easy-to-use packaging provides relief for those on-the-go so you can be chill whatever the occasion (long lines for the grocery store, strangers refusing to wear a mask, disposable gloves all over the ground the usual).

6. Activist Skincare Healing Water Toning MistThe vegan skincare connoisseurs at Activist believe self-care is fuel for the activism we should all be doing every day. So while youre making calls, advocating for marginalized communities, and attending protests (safely and with a mask), remember to take a moment for yourself. Add this hydrating, hyaluronic mist to your desk essentials for a small, calming break. The matte glass, recyclable bottle adds an elegant design to your workstation and the refreshing scent of cucumbers instantly calms.

7. Tata Harper Aromatic Irritability TreatmentIs your work-from-home buddy chewing their cereal as loudly as possible before youve had your cup of coffee? Instead of blasting your headphones, try this essential oil blend from natural beauty queen Tata Harper. Dab a few drops onto palms, rub together, and inhale deeply for an instant mood-lifting hit of balancing jasmine, fresh geranium, and soothing cypress.

8. Facialworks Sonic Wave + Coast Is Clear DuoMissing your monthly facials? Orange County-based, non-toxic spa specialists Facialworks brings the expertise straight to your home. With its extraction duo, you can prepare skin for a painless mini-facial and use the ultrasonic skin spatula to cleanse, get rid of blackheads or pimples, and infuse serums for maximum absorption. Clear skin, here we come!

9. The Good Patch Be Calm PatchPatches are the new It item for wellness brandsfrom pimple zappers to calming mood boosters like this menthol-infused stick-on from The Good Patch. Simply peel and stick on your wrist (or other veiny part of your skin) for over eight hours and feel nerves calm by the mix of hemp and other natural ingredients.

10.ORPHEUS Resurrection All-In-One SerumInspired by the regenerative powers of the haberlea rhodopensis flower found in the mountains of Bulgaria, family-run business ORPHEUS spent more than 20 years researching the properties of the rare blossom. Now, theyve packed the unique plants stem cells into this all-in-one serum to craft a richly intensive, calming experience for stressed-out skin. Thats pretty much all you could ask for in a bottle.

11. Missionary Chocolates CBD TrufflesA chocolate a day keeps the doctor away or something like that. Naturopathic physician Melissa Berrys Portland-based Missionary Chocolates crafts the meltiest hemp-derived fair-trade chocolates for the ultimate mid-day pick-me-up. Plus, with its cute packaging, you can send your loved ones a treat to get through the hard days.

12. The Nue Co Magnesium SprayStaring at the ceiling for hours when bedtime rolls around? Its cooljust spray this sleep aid spray from The Nue Co. made with high-quality magnesiuma mineral that is essential for over 325 biochemical reactions in the bodyand youll soon stop counting sheep. You can also use it as a post-workout aid for faster muscle recovery.

13. Life & Apples Wellness Journal Planners are a useful tool to track your busy schedule, but they can also be beneficial for checking in with yourself. Made of eco-friendly, vegan materials, this 90-day rose gold journal makes it simple to track habits, plan healthy meals, and set weekly goals. Plus, you can write down what youre grateful for to begin day on a bright note.

14. Four Sigmatic Lions Mane ElixirCaffeine levels through the roof? Same here. Thats why Im turning to lions mane, a favorite mushroom among researchers and herbalists touting benefits such as boosting mood, supporting cognitive function, and providing physical energy. Add to smoothies, decaf coffee, and tea to get a boost of brain-healthy nootropics.

15. Derma-E Vitamin C Bright Eyes Hydro Gel PatchesNon-stop screen-time is sure to wreak havoc on your eye health. When suffering from tired, baggy eyes, turn to Derma-Es moisture-intensive gel patches before your morning Zoom call. These sparkly yellow gels contain allantoin to increase smoothness, caffeine to reduce puffiness, and vitamins C and B3 to target fine lines, wrinkles, and dullness.

16. Rosebud Awaken CBD Bath SoakIf youre one of the rare types that like to take baths in the mornings, this uplifting, magnesium-rich soak is for you. With notes of bergamot and orange essential oils, 50mg of CBD, and calming Epsom salts, heck, Im considering waking up an hour earlier (wish me luck) to run a warm bath and start the day on a much chiller note.

17. REN Clean Skincare Atlantic Kelp and Magnesium Salt Anti-Fatigue Exfoliating Body ScrubExfoliate your hard-working body with a fresh body scrub from sustainability-focused REN Clean Skincare designed to gently polish and smooth skin with fresh sea and Epsom salts. Breathe in sage, cypress, geranium, and rosemary for an uplifting start to the day.

18. No B.S. Charcoal Detox Peel-Off MaskTheres just something so satisfying about a peel-off mask, but when it takes forever to take off while also causing wincing pain, wed rather avoid it altogether. Enter: cruelty-free and vegan skincare brand No B.S.s purifying, activated charcoal mask. In less than 20 minutes, watch the clean, pH-balanced formulation gently peel away the days impurities and reveal smooth, bright skin.

19. Buddha Teas Peppermint CBD TeaRather than using hemp oil like many other CBD teas, Buddha Teas figured out a way to use dispersible water-soluble CBD, ensuring optimal bioavailability and maximum absorption of the calming, non-psychoactive compound. With flavors such as Turmeric & Ginger, Matcha Green, and Peppermint, grab your tea setsits time for relaxation!

20. Pacifica Overnight Vegan Collagen Recovery CreamYour skin repairs itself at night, making the products used for your nighttime ritual all the more important. For those needing a little more glow, this Pacifica recovery cream infuses vegan collagen, essential lipids, antioxidants, and flower extracts to work some magic during your beauty sleep. Glowing, radiant skin, were dreaming of you!

21. Future Kind Vegan Sleep SupplementsStress hits hard at night when youre trying to get your Zzzs, which is why brothers and nutritionists Shaun & Eliot Cunningham developed Future Kinds eight-ingredient, all-natural sleep supplement that promises to have you feeling energized the next morningnot sluggishthanks to the addition of L-theanine.

22. Peak + Valley Balance My Stress BlendThrough the use of adaptogens such as reishi mushroom, eleuthero root, and ashwagandha, Black-owned wellness brand Peak + Valleys chocolaty, earthy stress blend pairs well with an afternoon tea or a warm cup of oat milk to protect the immune system and decrease fatigue.

23. HERBIVORE CALM Soaking SaltsEveryones favorite Himalayan pink salt blends with ylang-ylang and vanilla to soothe the body with this bath soak from plant-based, sustainable skincare brand HERBIVORE. Dont forget to recycle the chic glass bottle to reduce waste.

24. Heartsong Herbs Anxiety Away SupplementUsing regenerative growing practices to preserve soil and create stronger, more potent plants, small farm Heartsong Herbs takes its agriculture seriously. Crafting high-quality tinctures, the apothecarys Anxiety Away pairs herbs such as skullcap, passionflower, blue vervain, and lemon balm to ease away worries and help you feel grounded.

25. Kin Euphorics High RhodeNot in the mood for another lengthy Zoom happy hour and the inevitable hangover in the A.M.? Dont fret, you can still catch up with friends without the pressure. Grab a can of non-alcoholic High Rhodean herbaceous drink promising a state of bliss through a holistic mix of adaptogens, nootropics, and botanics. Kiss the morning-after headaches goodbye!

26. Naipo Massage GunWe cant go to a spa for an hour-long deep-tissue massage, so why not bring it home? This Naipo massager puts in the work and all you have to do is hold it over tense muscles to alleviate stiffness and relieve any pain. The portable design plus long battery life means you can keep it near you at all times for when the soreness starts to set in.

27. Asop Istros Aromatique Room Spray Weve all had to keep our imaginations alive during the months-long quarantine, so spend a few minutes daydreaming a walk through a lively, smoky Greek bazaar to get the creative juices flowing during a mid-day slump. Cult-favorite plant-based skincare brand Asops room spray should help with notes of pink pepper, lavender, tobacco.

Aruka Sanchir (@arukasanchir)is the Beauty & Style Editor at VegNews and shes always trying out new calming products to find her ultimate Zen.

Please support independent vegan media and get the very best in news, recipes, travel, beauty, products, and more.Subscribe now to the worlds #1 plant-based magazine!

See more here:
27 De-Stressing Vegan Products to Help You Get Through The Rest of 2020 - VegNews

Reportspedia announces a new report titled GlobalSkin Care Cosmetic Market, which outlines the rationale standpoint of the unpretentious forces of the market. It announces the addition of another new dimension to this industry explaining the performance of the major players. The Skin Care Cosmetic Market has also been segmented on the basis of the provincial players, out of which some are well established while some have newly entered the global market. These players have established actions such as research and development, determined to bring in new services that can efficiently compete with the other established players.

Get a sample of Skin Care Cosmetic Market @

https://www.reportspedia.com/report/life-sciences/2015-2027-global-skin-care-cosmetic-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/59849#request_sample

Top Key Players:

The Body Shop International PLCKao CorporationUnilever PLCAvon Products IncJohnson & JohnsonProcter & GambleBeiersdorf AGLOreal S.A.The Estee Lauder Companies Inc

Geographically, the following regions are covered in this report:

United States, Canada, Germany, UK, France, Spain, Russia, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

The global Skin Care Cosmetic Market report covers the market landscape and its growth over the upcoming years and discussion of the Prominent Companies effective in this market. This report has been organized based on a detailed market analysis with inputs from industry experts. The report delivers a 360-degree overview of the market, listing numerous factors limiting, driving the market during the forecast period.

Get a Huge discount on this Skin Care Cosmetic Market Research Report:

https://www.reportspedia.com/discount_inquiry/discount/59849

Skin Care Cosmetic Market Segment by Type:

Sensitive Skin CareDry Skin CareInfants Skin CareOthers

Skin Care Cosmetic Market Segment by Application:

Stem Cells Protection Against UVFlakiness ReductionRehydrate the Skin SurfaceMinimize wrinklesIncrease the viscosity of Aqueous

The global Skin Care Cosmetic Market is predicted to witness of enormous growth in the next six years. The growing level of competition among the players and the growing focus on the advance of new products are likely to offer promising growth during the prediction period. The research study on the global Skin Care Cosmetic Market deals with a complete overview, highlighting the key aspects that are projected to surge the growth of the market in the near future.

Inquire Before Buying @:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-skin-care-cosmetic-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/59849#inquiry_before_buying

Key Takeaways of the report

Some Points from Table of Contents

Global Skin Care Cosmetic Market Insight and Forecast to 2027

Chapter 1Skin Care Cosmetic Market Report Overview

Chapter 2Global Growth Trends

Chapter 3Market Competition by Manufacturers

Chapter 4Skin Care Cosmetic by Regions

Chapter 5Skin Care Cosmetic by Region

Chapter 6Skin Care Cosmetic Market by Type (2020-2027)

Chapter 7Skin Care Cosmetic Market by Application (2020-2027)

strong>Chapter 8Company Profiles and Key Figures in Skin Care Cosmetic Business

Chapter 9Production and Supply Forecast

Chapter 10 Marketing Channel, Distributors, and Customers

Chapter 11 Industry Trends and Advanced Strategy

Chapter 12Conclusions

Chapter 13Appendix

Get a Complete Table of Content, Just click on the below link @:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-skin-care-cosmetic-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/59849#table_of_contents

Here is the original post:
Global Skin Care Cosmetic Market 2020-2026 is Growing Rapidly and Expected to Witness a Sustainable Growth over 2027 - Scientect

Seeing a child debilitated by illness is never easy.

When doctors tell youthere is nothing they nor you can do to help ease yourbaby's suffering, well, parents who know that type of helplessness often find it hard to describe.

We were told to take my son home and love him, becausehe probably wouldnt live past his second birthday, said Pace father Todd Hamrick. But, were way past that birthday now.

Hamricks son, Alek, was diagnosed at six months old with spinal muscular atrophy and not expected to live long enough to toddle. ButAlek, now 3, has beaten the odds and outlived that initial, bleak prognosis.

His parents attribute much of his success to his doctor, Richard Finkel, who entered Alek into a clinical trial for what they believe has been a wonder drug for their little boy, Evrysdi, which was recently approved by the Food and Drug Administration.

Whats hard to even get around is that people even bothered to research it, Todd Hamrick said. Its just a small amount of the population that has SMA. Its not like researching a blood pressure medication.

Spinal muscular atrophy, or SMA,is a genetic disorder caused by a loss of nerve cells that effect human motor function.

Essentially, those afflicted by SMA are made weak. Their muscleswaste away. In many cases, eventually, a person loses their ability to walk, to eat andevento breathe, and they die.

Aleks mother, Iwona Hamrick, is a nurse at a local hospital and wellremembers the moment she heardher sons diagnosis.

It was unimaginable. His pregnancy was normal, she said. We did genetic testing and it was negative. Unfortunately, at that time, they were not screening for his disease. So, from a healthy baby to a dying baby, you know?

The parents felt they had to travel, in more ways than one, to find the places and help that they could for their Alek.

Todd Hamrick said that he and wife decided to move from Gulf Breeze to Pace after Aleks diagnosis after feeling ostracized by many of their former acquaintances. The parents felt like some people who they used to know were made uncomfortable by their son's illness.

The area is very in-the-dark when it comes to children with issues, Todd Hamrick said. If your kids are healthy and you'rehealthy, its a great area. But, it doesnt attract the greatest talent or best and biggest facilities or endowments.

So, Alek traveled with his family to meet his future doctor, Finkel, at the Nemours Children's Hospital in Orlando.

Alekwas first treated with a gene therapy drug, and he made some response with that, Finkel told the News Journal. But more recently, he started on a second drug, which seems to be having an enhanced effect, I must say.

Finkel, an expert in the field of pediatric neurologic disorders, left Florida in March for a position leading the new Center for Experimental Neurotherapeutics at St. Jude Childrens Research Hospital in Memphis, Tennessee. Buthe has continued to monitor Aleks progress via video.

Both of the drugs he has received, the gene therapy and this new drug, Evrysdi, are designed to increase a certain protein in Aleks body that is deficient because of his genetic disorder, he explained. But they do it in different ways. The potential advantage of his new drug, Evrysdi because its an oral drug; you take it by mouth it goes into the stomach and into the bloodstream, and from there, it goes to all the tissues of the body.

And, we think that there is an enhanced effect, becauseit gets into the muscle tissue, Finkel continued. "These are very, very, early daysin trying to make assessments, soI dont want to say that we can come to any kind of conclusions yet."

However the cutting-edge drug works doesnt matter to a mother, whos just glad that it isworking.

It gave us hope. Thats for sure, Iwona Hamrick said. Becausewe felt helpless.

Since Alek started his new treatment last November, his strength has increased tremendously.

His muscle tone got better, Iwona Hamrick said. He is much stronger in the upper body, so much so, he is pushing his little wheelchair.

Alek can now cruise around his Pace home in an extraordinarily lite-weight wheelchair designed by a Swedish inventor who alsohas a child with SMA.

Alek had a lot of trouble before starting this medication even pushing it, Iwona Hamrick said. Sonowhe is just rolling around the house. Also, he is barring more weight on his legs.

Recently, Alek has started to be able to walk in a pool a huge milestone for the toddler.

But some worries remain the same.

Every day, Alek must use a type of breathing machine.

Its a cough assist machine, Todd Hamrick explained. We use it two times a day, when hes healthy. Becausewhere we can just clear our throats when we cough, he doesnt have that strength no lung strength.

Alek attends physical therapy, aqua-therapy,hippotherapy, occupational therapy and speech therapy sessions every week to try and ensure he remains healthy and continues to properly develop.

My worries have changed a lot, Todd Hamrick said. I used to worry my child was going to die. Now, Im worrying about if other kids will bully him at school.

"But that'sa great worry to have," he continued. "Compared to how it use to be, getting picked on is a great thing to worry about.

Colin Warren-Hicks can be reached at colinwarrenhicks@pnj.com or 850-435-8680.

Read or Share this story: https://www.pnj.com/story/news/2020/09/08/pace-florida-toddler-spinal-muscular-atrophy-helped-drug-evrysdi/5681766002/

Visit link:
Pace toddler wasn't supposed to survive. Thanks to wonder drug, parents say he's thriving - Pensacola News Journal

Equipment required for reactor pressure vessel annealing has been delivered to the Armenian nuclear power plant.

The annealing will be carried out as part of the project to modernise and extend the life of unit 2 of the Armenian NPP. The plant will be prepared for the final part of the work on extending its service life, which will take place in 2021 - the reactor will be annealed, which will allow it to return to 80-85% of its original state by, the press service of Rosatom reported on 4 September.

This is an important science-intensive work to improve plant safety. Annealing will restore the characteristics of the metal of the reactor vessel, which will allow it to be safely operated in the future, said Yuri Sviridenko, manager for the life extension project.

The vessel will be annealed after the fuel assemblies have been unloaded into the used fuel pool. The vessel will be inspected and the equipment installed in the reactor. Using an annealing unit, the reactor vessel will be heated to a temperature of 475 degrees Celsius, kept at this temperature for several days, after which it will slowly cool down.

The procedure will be carried out by several Rosatom organisations, each of which is responsible for its own segment of the work.

This technology for recovery annealing of the reactor vessel metal was first applied in 1987 at Novovoronezh 3. Now this procedure is carried out at all plants requiring service life extension. Reactor pressure vessel annealing has already been completed at VVER-440 reactors at Kola in Russia, Rovno in Ukraine, Kozloduy in Bulgaria and Loviisa in Finland.

Unit 2 of Armenian nuclear power plant was reconnected to the grid on 1 September after being closed for scheduled repairs, Rosatom said.

The work performed has made it possible to significantly increase the level of safety and reliability of the power unit. Preventive maintenance at the Armenian NPP was completed 12 days ahead of schedule, Rosatom said. This was possible due to the efficient organisation of the process, the focus of the personnel of the Armenian NPP on results, as well as mutual understanding and effective business relations with the involved organisations that were developed during the joint work."

Rusatom Service, part of Rosatoms electric power division, was the general contractor for the work. For the fifth year now, the Armenian NPP has been combining maintenance work with the implementation of a programme to extend the life of the plant, since most of the activities in this direction are technologically available only when the unit is shut down, Rosatom noted. After completion of the maintenance activities, life extension work continues.

Armenias state programme provides for the extension of the operating life of the existing NPP unit until 2026, as well as the phased commissioning of new units. Funding was provided by a Russian state export loan of $270 million and a grant of $30 million for up to 15 years. However, earlier this year Armenia refused to extend the loan preferring to finance further work at its own expense. The Armenian government provided a budgetary loan to the Armenian NPP in the amount of $131.38 million for 2020-22, while the cost of the agreement with Rusatom Service is limited to $40.255 million.

The two-unit Armenian nuclear plant was built in the 1970s, but was closed following the Spitak earthquake in 1988. Metsamor 2 restarted with Russian assistance in 1995 in the face of severe energy shortages.

Link:
Key life extension equipment delivered to Armenian NPP - Nuclear Engineering

A landfill site owners plan to add 15 years to the life of its contentious commercial and municipal waste tip has been thrown out.

FCC Environment runs the Bletchley Landfill Site, near Newton Leys, and it applied to Milton Keynes Council to add another 15 years to its operational life.

The tip is due to close in 2022 under permission granted in 2002, but the application would see it taking commercial and council waste until 2037 with another two years to finish off restoration work.

One of the objectors, resident Ethan Kelly-Wilson told Thursdays development control committee that he would be nearing retirement, and his child would be grown up before the site would be returned to nature.

Other objectors also made the case that residents, especially in Newton Leys, had brought their new homes on the understanding that they would only have to put up with the site for a few more years.

Adding 15 years would have a devastating impact, said Bletchley and Fenny Town councillor Ed Hume.

Mat Nicholson, the estates manager for owner FCC Environment, said he had concerns over the manner which some of the information was presented to the committee.

He claimed that it was in a manner not to give the full picture.

He said that the site, which employs 15 people, is regionally important, making up one quarter of the landfill space that is left in the whole of the south east of England.

Mr Nicholson said none of the statutory consultees had objected but that was not highlighted to the committee.

He claimed that consultees like the Environment Agency and the councils own environmental health officers were not given equal weight to other issues.

He admitted there had been a large number of recent complaints but claimed there is a disparity between complaints and reality.

Mr Nicholson added that if the life of the site was not extended then it would not be possible to restore the site as agreed. And he said it would cause issues with site gases and water.

But Tracy Darke, the councils director of economy, growth and culture, said councillors had to make a judgement on where the planning balance lies by taking everything into account.

Residents expected to have a country park in 2023 but in 2035 we could be in exactly the same position.

There is no clarity around when we get to the end date anyway.

Ward councillor Emily Darlington (Lab, Bletchley East) said having a landfill site in Milton Keynes until 2037 would go against the citys aim to be the greenest city.

And other speakers said they did not want Milton Keynes to be an exporter of other peoples rubbish when the council is aiming to send nothing at all to landfill.

Cllr Paul Trendall (Lib Dem, Campbell Park & Old Woughton) said: MK isnt everyones dumping ground.

Councillors voted unanimously to reject the application. FCC Environment will have the opportunity to appeal to the Government to get an inspector to overturn the committees decision.

See the original post here:
Committee rejects owner's case to throw out 15 year landfill site life extension plan in Milton Keynes - MKFM

The most recent research released provided interesting results. Quite interesting.

Of all of the countries in the world all of them where do you think the United States ranks with respect to the increase in human longevity? That is, in which countries are people living longer. (This came out pre-virus.)

It might be significant to point out that both individually and in the aggregate, the U.S. ranks first by a healthy margin in money spent on health care. Then, it might not.

You see, as a country we rank 45th overall in life extension.

Of utmost significance, experts say the primary cause of this less than stellar ranking is, in a word diet.

Thats right, diet. What we eat. How its prepared and seasoned. (Think animal fat, fried, fast foods.) And individual amounts. How much, that is.

Just look at us, folks. Overweight or obese is almost standard. Especially is this so in places such as where we live. In rural areas. In the South. Not an opinion. A fact.

Lets not just say diet and leave it at that. It is estimated that 68 percent of adults are overweight and 34 percent are obese.

An ideal heart-healthy diet as defined by the American Heart Association entails that saturated and trans-fat should be limited to less than seven percent and one percent of your daily calories, respectively Additionally, physical activity can help control weight and improve cardiovascular health. It is recommended to exercise 30 minutes a day, five days a week. (Rony L. Shammas, MD, FACC, FASE, FSCAI, Vidant Medical Center)

Smoking? We dont even need to go there. We all know that it is a strong risk factor for heart attack, stroke and cancer.

Then, we could cite grim warnings about cholesterol, high blood pressure and diabetes, of course. But most of us have long known about all of this. Some are in denial, and some are going to do what they want to do, all information and warnings be damned. And that includes those now who also dont respect the coronavirus.

A good friend of mine would often say that You cant save people from themselves.

And that, friends, is the way it is.

Read the original:
Write Again ... The primary cause - Washington Daily News - thewashingtondailynews.com

Greece and Turkey have a long history of animosity despite both being NATO members. However, theres a real concern that the current spike in tensions mainly related to control of oil and gas reserves and maritime rights in the eastern Mediterranean could escalate. If they do, the respective air arms of the two countries are likely to be heavily engaged, so its a good time to take a detailed look at their respective assets and how their capabilities compare.

Its worth noting here that the Hellenic and Turkish Air Forces regularly spar over the Aegean Sea. Turkey and Greece broadly have a long history of confrontation, including an all-out war fought in support of competing factions in Cyprus in 1974. That independent Mediterranean island, which is still divided between areas under the control of ethnic Greek and Turkish Cypriots to this day, remains a focus of antagonism between the two countries. However, current developments in the region have caused alarm in both NATO and the European Union.

The background to the current dispute surrounds the race to exploit energy reserves in the eastern Mediterranean. The two countries have claims on overlapping areas containing undersea oil and gas fields. In July, Turkey announced it was sending its research vessel Oru Reis to carry out a drilling survey in disputed waters off the coast of southwest Turkey, but close to the Greek island of Kastellorizo. The Greek military was put on alert and the vessel eventually left port on August 10, 2020.

NormanEinstein/wikicommons

The illegal and provocative behavior of Turkey has a serious backlash not only to peace and stability in the eastern Mediterranean but to the cohesion of NATO and to its relations with the European Union, said Greek Foreign Minister Nikos Dendias, in response to the Turkish drilling mission.

Greece claims 40,000 square kilometers of maritime jurisdiction area due to this tiny island [Kastellorizo] and attempts to stop the Oru Reis and block Turkey in the eastern Mediterranean, declared aatay Erciyes, Director General at the Turkish Ministry of Foreign Affairs.

The build-up to the latest phase in the standoff included a collision between Greek and Turkish frigates on August 12, 2020. The Turkish warship involved was one of five escorting the research vessel OruReis. The Greek frigate Limnos made contact with its Turkish counterpart Kemal Reis and the resulting damage was apparently confirmed by photos published soon afterward in the Greek media.

Complicating matters, some of the recent exercises in the area have involved foreign participation, including French Air Force Rafale fighter jets that arrived at Souda-Chania Air Base on Crete for joint training with Greek F-16s on August 13, 2020. The French Ministry of Defense described the deployment as a temporarily strengthening [of] their presence in the eastern Mediterranean. Souda then received four F-16E/F Desert Falcons from the United Arab Emirates, which had touched down at the Greek base by August 27 to take part in further joint exercises.

On August 26, Greece began a naval exercise south of Cyprus involving forces from Cyprus, France, and Italy. At the same time, warships from Turkey and the United States were taking part in separate drills in the same area. The U.S. Navy has taken part in maneuvers with both the Greek and Turkish navies in recent weeks, including involvement from Greek F-16s and the U.S. Navy Arleigh Burke-class destroyer USS Winston S. Churchill.

U.S. NAVY/MASS COMMUNICATION SPECIALIST 3RD CLASS LOUIS THOMPSON STAATS IV

The Arleigh Burke-class guided-missile destroyer USS Winston S. Churchill (DDG 81) executes drills with the Hellenic Navy frigate Aigaion (F 460) in the Mediterranean, August 24, 2020.

As well as a war of words and aggressive acts between ships, there have been other examples of direct posturing, too. The Turkish Ministry of Defense released what it claims is footage from the head-up display (HUD) of one of its F-16 fighters showing an incident that occurred on August 27, 2020, in which six Greek F-16s were supposedly warded off by Turkish Vipers. According to a statement from the ministry, the Greek fighters launched from Crete and were heading towards southern Cyprus when they approached an area in which Turkey had previously declared a restricted zone for a naval exercise.

The Turkish Ministry of Defense said the Greek jets were removed from the region and local media reported that the Oru Reis was also active in the area at the time. The supplied HUD footage shows F-16s in a turning fight at close quarters and includes several tone alerts indicating that the Turkish pilots AIM-9 Sidewinder air-to-air missile (AAM) was locked on to the opposing F-16. The full story behind the incident is unclear, but encounters of this kind are not uncommon over the contested waters of the Aegean. However, by posting the video now, the Turkish Ministry of Defense seems keen to display its willingness and ability to take on Greek airpower to protect its interests in the region.

The most recent altercations between Greek and Turkish forces, and the soaring rhetoric that has come with them, have been met with concern among the wider European Union, of which Greece is a member. The German Defense Minister, Annegret Kramp-Karrenbauer, has called for the situation in the Aegean to be defused and criticized the latest rounds of potentially provocative naval exercises staged by both countries in the area. Kramp-Karrenbauers words suggest theres now a wider recognition that another incident could put Greece and Turkey on a more serious collision course again, including in the air.

NATO Secretary General Jens Stoltenberg spoke with Turkish President Recep Tayyip Erdoan on August 28, 2020, to talk about developments in the eastern Mediterranean. Stoltenberg stressed dialogue and de-escalation and the two discussed deconfliction mechanisms to prevent further incidents. For NATO, any tensions between Greece and Turkey threaten the solidarity of the alliance, potentially diminishing its ability to confront common security challenges.

Were urging everyone to stand down to reduce tensions and begin to have diplomatic discussions added U.S. Secretary of State Mike Pompeo. It is not useful to increase military tensions in the region.

After examining the background to the latest standoff, lets look at the key combat aircraft types that make up the two countries respective air arms.

The two countries air forces are spearheaded today by Lockheed Martin F-16 Viper fleets, which have now recorded three decades of service in Greece and Turkey. In both cases, the fighter jets were primarily purchased to replace aging F-104 Starfighters and F-5 Freedom Fighters.

The Hellenic Air Force (HAF, or Elliniki Polemiki Aeroporia) received 170 F-16s of various types between 1989 and 2010 and, with a large-scale modernization program underway, the Viper will remain the backbone of the air arm for many years to come.

HELLENIC AIR FORCE

A Hellenic Air Force F-16C Block 50 in the markings of 341 Mira and armed with AGM-88 HARMs.

Greek Vipers were acquired via Foreign Military Sales (FMS) channels, through the Peace Xenia program, which included four distinct phases.

Peace Xenia I provided 34 single-seat F-16C and six two-seat F-16D Block 30 jets delivered between 1988 and 1990.

Peace Xenia II added another 32 F-16C and eight F-16D Block 50 aircraft. These jets are capable of night attack missions with the LANTIRN targeting pod and have AGM-88 High-speed Anti-Radiation Missile (HARM) capability, making them suitable for the suppression/destruction of enemy air defenses (SEAD/DEAD) mission.

Peace Xenia III provided 40 F-16C and 20 F-16D Block 52+ jets, all equipped with conformal fuel tanks for extended range. These were delivered between 2003 and 2004.

After scrapping plans to purchase the Eurofighter Typhoon, the Greek government instead opted for another Viper order, under Peace Xenia IV, to replace the veteran fleet of A-7H/TA-7H Corsair II attack jets. The deal covered 20 F-16C and 10 F-16D Block 52+ Advanced versions, also sometimes referred to as Block 52M aircraft, and was signed in December 2005.

The HAFs aging F-16 Block 30s are now consolidated with a single squadron, 330 Mira, and the jets have undergone the Falcon UP service-life extension, work being undertaken locally by Hellenic Aerospace Industry (HAI).

Of the 150 or so Vipers still operational, the bulk is divided among eight operational squadrons based at Araxos, Lrisa, Na Anghialos, and Souda-Chania, but the HAF also maintains a number of rotational detachments on islands in the Aegean. All HAF F-16 squadrons maintain a full air-to-air capability and undertake quick reaction alert (QRA) readiness duties to counter potential Turkish airspace violations, despite the fact that some are specialized air-to-ground squadrons.

The Collins Aerospace DB-110 reconnaissance pod is available to Greek F-16s for reconnaissance missions, and additional weapons options include the AIM-120C AMRAAM, AGM-154C Joint Stand-Off Weapon (JSOW), Joint Direct Attack Munition (JDAM), and reportedly Wind Corrected Munitions Dispensers (WCMD). Unusually, the HAF has opted for the pan-European IRIS-T as the primary short-range AAM for the Viper, rather than the AIM-9X Sidewinder.

Eyeing a longer-term modernization for its Vipers, Greece selected the F-16V upgrade that will bring 84 aircraft all of them Block 52+ and Block 52+ Advanced jets to Block 70/72 standard, including the AN/APG-83 Scalable Agile Beam Radar (SABR) with active electronically scanned array (AESA), Raytheon Modular Mission Computer, remodeled cockpit including the second-generation Joint Helmet Mounted Cueing System (JHMCS ), and the Link 16 data link, among other enhancements. Most of the work will be undertaken by HAI in Greece. There have been suggestions that the remaining 38 Block 50 jets could also undergo an upgrade, bringing them to a so-called Block 50+ Advanced standard, but this hasnt been contracted. The fate of the Block 30 aircraft is unclear, but they could be sold off, or perhaps used as aggressors for air defense training.

TURKISH MINISTRY OF NATIONAL DEFENSE

A Turkish Air Force F-16 pair heads out for a training mission, led by an F-16C Block 50.

On the other side, the Turkish Air Force, or Trk Hava Kuvvetleri (THK), is the worlds third-largest Viper operator, with a total of 270 aircraft delivered in successively more capable Block 30, Block 50 and Block 50+ configurations.

Local industry also plays a significant part in the Turkish Viper program, with involvement from Turkish Aerospace Industries (TAI) from the outset, including local assembly of aircraft and production of center/aft fuselage sections and wings.

The Turkish Viper procurement took place in four phases: Peace Onyx I to IV.

Under Peace Onyx I, Turkey received 136 F-16Cs and 24 F-16Ds, of which the first 44 were completed to Block 30 standard. The next 116 aircraft within Peace Onyx I were Block 40-standard jets that included the provision for LANTIRN pods. Deliveries took place from 1987.

Peace Onyx II covered 60 F-16C and 20 F-16D Block 50 aircraft, which were delivered between 1996 and 1999. Like the HAF Vipers, Turkish F-16 Block 50s were provided with the AGM-88 HARM anti-radiation missile.

The Peace Onyx III contract provided the Common Configuration Implementation Program (CCIP) upgrade. As well as adding more sophisticated weapons and sensors, this improved logistics support and reduced life-cycle costs. Lockheed Martin provided a total of 163 CCIP kits for Turkeys surviving F-16C/D Block 40/50s. After modernization, the aircraft featured APG-68(V)9 multi-mode radar, color cockpit displays and recorders, JHMCS, Link 16 data link, Sniper targeting pods, and new weapons, including the AGM-84K Joint Standoff Land Attack Missile Expanded Response (SLAM-ER), AGM-154A/C JSOW, AIM-9X, and CBU-103/105 Wind Corrected Munitions Dispensers (WCMD). Other weapons available to Turkish Vipers include the AIM-120 AMRAAM as well as the AGM-65 Maverick TV-guided air-to-ground missile.

The most recent Peace Onyx IV program provided another 14 F-16C and 16 F-16D Block 50+ jets, which are known to be compatible with the 1,300-pound Roketsan Stand-Off Missile (SOM) for standoff precision strike, as well as other indigenous weapons. These aircraft were delivered between June 2011 and December 2012.

More recently, TAI has set about upgrading 35 of its oldest Block 30 Vipers. This is based around a service-life extension using kits supplied by Lockheed Martin. The status of this program is currently uncertain, with reports that the U.S. Congress may have blocked the contract in response to Ankaras purchase of the S-400 air defense system.

Today, the THKs F-16C/D fleet is operated by two squadrons at Balikesir, two squadrons at Bandirma, two squadrons at Diyarbakir, one squadron at Eskiehir, one squadron at Konya, and two squadrons at Merzifon. Units are assigned particular roles, among them air defense, SEAD/DEAD, tactical air support for maritime operations, close air support, reconnaissance, and aggressor.

Eskiehir is home to 113 Filo, a former RF-4E operator, which is assigned the DB-110 reconnaissance pod that is used with the F-16, four of these pods having been acquired.

F-16 inventory (this and subsequent similar data is provided by Flight InternationalsWorld Air Forces 2020 publication):

Greece: 153

Turkey: 245

The Hellenic Air Force also operates the Mirage 2000 multi-role fighter, having acquired two distinct versions of the delta-wing jet. The first order was placed for 36 single-seat Mirage 2000EGs and four two-seat Mirage 2000DGs and deliveries began in 1988. Although being used primarily for air defense, these aircraft can be armed with the AM.39 Exocet anti-ship missile.

HELLENIC AIR FORCE

Afterburner take-off for a Hellenic Air Force Mirage 2000-5EG.

The HAF subsequently obtained a further 15 new-build Mirage 2000-5BG/EG (Mirage 2000-5 Mk 2) jets and brought 10 of its earlier aircraft to the same standard. One reason for adding the more capable Mirage 2000-5 Mk 2 may have been to match the beyond-visual-range capabilities of Turkeys F-16s armed with AIM-120 AMRAAM missiles. The French-made jets are armed with the MBDA MICA missile, available in both radar-guided and infrared-guided variants.

The Greek Mirage 2000-5 Mk 2 jets also have an important long-range conventional strike role with the MBDA SCALP-EG cruise missile. A first airframe upgraded by HAI took to the air in 2005 and the first new-built fighters from Dassault began to arrive in Greece in 2007.

The HAFs Mirage fleet is divided between two squadrons based at Tangra, and the jets also conduct rotational detachments to islands in the Aegean.

Mirage 2000 inventory:

Greece: 42

As well as both flying the F-16, Greece and Turkey are among the last operators of the F-4 Phantom II. However, both countries have now retired their reconnaissance-configured RF-4 fleets.

The Hellenic Air Force has a single unit operating F-4E fighters that were upgraded to Peace Icarus 2000 standard under the Avionics Upgrade Program (AUP) between 1997 and 2001. Stationed at Andravida near the west coast of the Peloponnese peninsula, these jets are multi-role-capable, but its thought they now focus on air-to-ground missions.

HELLENIC AIR FORCE

A Hellenic Air Force F-4E in its hardened aircraft shelter, armed with the Vietnam War-era HOBOS TV-guided bomb.

Among others, the AUP added AN/APG-65Y radar, inertial navigation system/GPS, AN/ALR-68(V)2 radar warning receiver, color multifunctional displays, a new head-up display, and hands on throttle and stick (HOTAS) controls. The Rafael Litening II laser targeting pod provides day/night precision targeting and weapons include laser-guided bombs, AGM-65 Maverick air-to-ground missiles, AIM-120 AMRAAM, and AIM-9 Sidewinder.

While 33 of the 36 Greek F-4Es that underwent the AUP remain operational, its thought that around 20 are actually available for operations at any given time.

Turkeys Phantoms also underwent a significant mid-life upgrade, emerging as the F-4E Terminator 2020. The modernization involved Israel Aircraft Industries (IAI) and covered 54 airframes, including structural and avionics work. The upgraded avionics include an Elta EL/M-2032 multi-mode radar, digital glass cockpit, wide-angle HUD, and HOTAS controls. The jets can be armed with the Israeli-made Popeye standoff missile, as well as the indigenous Roketsan SOM for use against land and sea targets. Other stores include the HGK 500-pound INS/GPS-guided bomb, KGK 500-pound or 1,000-pound glide bomb, and the LGK-82 an indigenous version of the 500-pound GBU-12 laser-guided bomb.

TURKISH MINISTRY OF NATIONAL DEFENSE

A pair of Turkish Air Force F-4E Terminator 2020s.

While both countries have made efforts to acquire new-generation fighters to modernize their fighter arms, Turkey was ejected from the F-35 stealth fighter program in response to its purchase of Russian-made S-400 air defense systems. Greece, meanwhile, has been identified as a possible F-35 customer too, and more recently unconfirmed reports have emerged in the Greek press that the country is examining a potential purchase of 18 Rafale multi-role fighters.

It was expected that the Turkish Phantoms would be retired with the arrival of the F-35, but with Ankaras expulsion from the Joint Strike Fighter program, its possible the THK F-4s will continue in service until around 2030, by which time the next-generation TF-X fighter may be available. Today, the F-4Es serve with a single squadron at Eskiehir.

F-4E inventory:

Greece: 33

Turkey: 48

Airborne early warning (AEW) is a critical function for modern complex air operations and both Greece and Turkey contribute to NATOs E-3A Sentry Component, which maintains a pooled fleet of the Airborne Warning and Control System (AWACS) aircraft at Geilenkirchen Air Base in Germany. The component also has forward operating bases at Aktion in Greece and Konya in Turkey. However, both countries have also established independent airborne early warning and control (AEW&C) capabilities.

HELLENIC AIR FORCE

The EMB-145H combines the Ericsson Erieye AESA radar with the Embraer EMB-145 bizjet airframe.

Greece opted for its own AEW&C solution in 1999 when it ordered four Embraer EMB-145H aircraft from an Embraer, Ericsson, and Thales consortium. The aircraft are equipped with Ericsson Erieye AESA radar. These aircraft also have a signals intelligence (SIGINT) capability using Elettronica ALR-733(V)5 electronic support measures (ESM). The Greek aircraft has five workstations and the mission crew typically comprises a radar operator, mission commander, SIGINT specialist, and two weapons controllers.

Prior to the delivery of the EMB-145H aircraft, the HAF leased a pair of S 100B Argus AEW&C aircraft from the Swedish Air Force for a two-year period as an interim solution. The EMB-145H aircraft have been operational at Elefsis, west of Athens, since 2009. Using the Link 11 and Link 16 networks, the Embraers can exchange data with airborne, naval, and ground-based assets.

BOEING

A pre-delivery shot of the fourth and final 737 AEW&C for Turkey.

Turkeys airborne early warning and control fleet is based around the Boeing 737 AEW&C that was acquired under the Peace Eagle program and is sometimes referred to by the local designation E-7T. The aircrafts primary sensor is the Northrop Grumman Multi-Role Electronically Scanned Array (MESA) surveillance radar. The impetus to acquire the aircraft seems to have been to fill the gaps in airspace coverage over Turkeys mountainous territory, where ground-based radars wouldnt necessarily detect high-speed, low-flying targets.

The Boeing 737 AEW&C was selected in 2000 and four examples were eventually ordered, the first provided by Boeing, while the remaining three were outfitted by TAI. The project experienced a number of delays, including as a result of a breakdown in relations between Ankara and Israel, the latter which was to provide the Elta ESM system. The first aircraft was finally delivered to the air force in 2014, six years late. Today, the four aircraft are stationed at Konya and as well as working with fighters and monitoring airspace over the Aegean, the fleet has been used to monitor movements along the Syrian border including reportedly tracking Wing Loong II drones operating over Libya. Unlike the HAFs EMB-145H, the 737 AEW&C can use inflight refueling to extend the duration of its missions.

AEW&C inventory

Greece: EMB-145H (4)

Turkey: 737 AEW&C (4)

With most combat operations anticipated to take place regionally, the Hellenic Air Force has a fairly modest tactical transport fleet. It also lacks an organic air-to-air refueling capability, meaning fighters would have to be refueled on the ground, perhaps at forward-located island airstrips. The air force operates around seven older C-130B/H Hercules airlifters, plus two more H-models modified for electronic intelligence (ELINT) missions. Surviving Hercules underwent an Avionics Upgrade Program (AUP) between 2005 and 2010, including modifications to the INS/GPS, autopilot, weather radar, and digital engine controls. A partially glass cockpit and revised electronic warfare system were also included.

HELLENIC AIR FORCE

A Hellenic Air Force C-27J Spartan tactical airlifter.

The HAF also flies eight more modern twin-turboprop C-27J Spartan tactical transports, delivered from 2005, although these have experienced limited availability in recent years. Mainly employed for airlift, the Spartans can also be used for medical evacuation and maritime patrol.

TURKISH MINISTRY OF NATIONAL DEFENSE

Three different Turkish Air Force tactical transports on the runway. From front to back: A400M, C-130, and C-160.

In contrast to the HAF, the Turkish Air Force has an aerial refueling capacity using seven KC-135R Stratotankers, which can deliver fuel via their boom or a boom-to-drogue adapter. For its transport needs, the THK relies upon around 16 C-130B/Es (airframes that are even older than those operated by Greece) and a diminishing number of Transall C-160Ds, as well as smaller CN235s, 42 of which were ordered and two of which have been adapted for ELINT duties.

The Turkish airlift fleet is also in the process of modernization through the induction of the A400M, and the last of 10 examples are scheduled to be handed over in 2022. Two C-160Ds have been adapted for communications jamming and can reportedly also undertake communications intelligence (COMINT) missions.

Tactical transport and tankers inventory

Greece: C-27J (8), C-130B/H (9)

Turkey: A400M (9), C-130B/E (16), C-160D (13), CN235 (42), KC-135R (7)

Both nations include fixed-wing maritime patrol aircraft (MPA) with anti-submarine warfare (ASW) capabilities and, although these are assigned to their respective naval air arms, there is some crossover as Greeces P-3 Orion aircraft are operated by Hellenic Air Force flight crews working alongside naval mission crews.

The Hellenic Navy ceased operations with its five P-3Bs in September 2009 before a mid-life upgrade and modernization program was launched, Lockheed Martin being awarded a $142-million, seven-year contract covering reactivation of one aircraft plus hardware and software for the other four. The first refurbished P-3B was handed over by HAI in Tanagra in May 2019.

LOCKHEED MARTIN

Official handover of the first refurbished P-3B to Hellenic Navy officials in May 2019.

The aircraft are initially undergoing an interim upgrade, but its planned for them to be brought up to full P-3HN standard that should provide another 20 years of service. This also includes an indigenous tactical mission suite, the Maritime Mission Integration and Management System (M2IMS). The Greek Orion fleet is stationed at Elefsis. Once back to full strength, the P-3 will provide Greece with a long-range maritime patrol capability to monitor the Mediterranean, and especially the Aegean, including the Aphrodite gas field off the coast of Cyprus.

Turkish MPA capability rests not with its air force but with its naval air arm. After the retirement of the veteran S-2 Tracker in the early 1990s, the Turkish Navy was left without a fixed-wing MPA capability until the launch of the Meltem project at the end of that decade. This has provided six MPA-configured CN235M-100 twin turboprops, acquired under Meltem I, and then outfitted with the Thales AMASCOS-300 (Airborne Maritime Situation and Control System) under Meltem II. For ASW missions, the aircraft can be armed with Mk 46 torpedoes.

Finally, the Turkish Meltem III program is now providing a more advanced MPA capability, based on the ATR 72-600 twin-engine turboprop, outfitted by Leonardo. The work has been subject to delays, however, and the first of six aircraft was reportedly still undergoing final tests in April 2020, having made a first post-conversion test flight back in 2014.

Maritime patrol inventory

Greece: P-3B (1, plus 4 to be refurbished)

Turkey: CN235M-100 MPA (6)

More:
Face-Off In The Aegean: How Greek And Turkish Air Forces Stack Up - The Drive

International pharmaceutical giants GSK and Sanofi have today announced that they have begun clinical trials of their coronavirus vaccine.

The two firms have revealed that 440 adults would be given doses of their vaccine at 11 sites across the US. The results are scheduled to be published in December with more trials scheduled to take place over the next few months.

The Anglo-French partnership uses the same protein-based technology as one of Sanofis influenza vaccines.

Thomas Triomphe, Executive Vice President and Global Head of Sanofi said: The initiation of our clinical study is an important step and brings us closer to a potential vaccine which could help defeat COVID-19. Our dedicated teams and partner continue to work around the clock as we aim to deliver first results in early December. Positive data will enable a prompt start of the pivotal phase three trial by the end of this year.

This follows the news last week the British firm AstraZeneca also began clinical trials in the UK.

The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics of AZD7442.1 The trial will include up to 48 healthy participants in the UK aged 18 to 55 years and is funded by the Defense Advanced Research Projects Agency (DARPA), part of the US Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: This trial is an important milestone in the development of our monoclonal antibody combination to prevent or treat COVID-19. This combination of antibodies, coupled to our proprietary half-life extension technology, has the potential to improve both the effectiveness and durability of use in addition to reducing the likelihood of viral resistance.

A new 500m funding package will be invested in next generation testing technology and increased testing capacity, the Health and Social Care Secretary announced today.

To date, large-scale COVID-19 testing system has carried out more than 16 million tests and this new funding for quick result test trials and repeat population testing will help take the programme to the next level.

A new, community-wide trial in Salford will launch imminently to assess the benefits of repeat population testing. Existing, promising trials in Southampton and Hampshire, using a saliva test and a rapid 20-minute test, will also be expanded using the new funding.

By using this cutting-edge technology to widely roll out rapid tests, chains of transmission will be broken almost immediately by delivering on-the-spot results. Successful trials will then be expanded and rolled out more widely.

The funding will also be used to further extend capacity for existing polymerase chain reaction (PCR) testing across the country. All positive results will be passed to the NHS Test and Trace system, to trace contacts, prevent further transmission, and save lives.

Health and Social Care Secretary Matt Hancock said: Testing is a vital line of defence in combating this pandemic. Over the past 6 months we have built almost from scratch one of the biggest testing systems in the world. We need to use every new innovation at our disposal to expand the use of testing, and build the mass testing capability that can help suppress the virus and enable more of the things that make life worth living. We are backing innovative new tests that are fast, accurate and easier to use and will maximise the impact and scale of testing, helping us to get back to a more normal way of life.

I am hugely grateful for the work being done on this national effort to strengthen our ability to tackle this virus. While we work on a vaccine we must innovate our way out of this crisis.

Trials across the country will now be launched or extended, with the latest starting in Salford today.

Read the original post:
GSK and Sanofi begin coronavirus vaccine trials in the UK and US - Business Leader

FCC Environment runs the Bletchley Landfill Site, near Newton Leys, and it applied to Milton Keynes Council to add another 15 years to its operational life.

The tip is due to close in 2022 under permission granted in 2002, but the application would see it taking commercial and council waste until 2037 with another two years to finish off restoration work.

One of the objectors, resident Ethan Kelly-Wilson told Thursdays development control committee that he would be nearing retirement, and his child would be grown up before the site would be returned to nature.

Other objectors also made the case that residents, especially in Newton Leys, had brought their new homes on the understanding that they would only have to put up with the site for a few more years.

Adding 15 years would have a devastating impact, said Bletchley and Fenny Town councillor Ed Hume.

Mat Nicholson, the estates manager for owner FCC Environment, said he had concerns over the manner which some of the information was presented to the committee.

He claimed that it was in a manner not to give the full picture.

He said that the site, which employs 15 people, is regionally important, making up one quarter of the landfill space that is left in the whole of the south east of England.

Mr Nicholson said none of the statutory consultees had objected but that was not highlighted to the committee.

He claimed that consultees like the Environment Agency and the councils own environmental health officers were not given equal weight to other issues.

He admitted there had been a large number of recent complaints but claimed there is a disparity between complaints and reality.

Mr Nicholson added that if the life of the site was not extended then it would not be possible to restore the site as agreed. And he said it would cause issues with site gases and water.

But Tracy Darke, the councils director of economy, growth and culture, said councillors had to make a judgement on where the planning balance lies by taking everything into account.

Residents expected to have a country park in 2023 but in 2035 we could be in exactly the same position.

There is no clarity around when we get to the end date anyway.

Ward councillor Emily Darlington (Lab, Bletchley East) said having a landfill site in Milton Keynes until 2037 would go against the citys aim to be the greenest city.

And other speakers said they did not want Milton Keynes to be an exporter of other peoples rubbish when the council is aiming to send nothing at all to landfill.

Cllr Paul Trendall (Lib Dem, Campbell Park & Old Woughton) said: MK isnt everyones dumping ground.

Councillors voted unanimously to reject the application. FCC Environment will have the opportunity to appeal to the Government to get an inspector to overturn the committees decision.

Follow this link:
Committee rejects owners case to throw out 15 year Milton Keynes landfill site's life extension plan - Milton Keynes Citizen

MarketResearch.Bizhas added the most recent research reportWorldwide Gene Therapy Market, this report assists with breaking down top makers, districts, and in like manner covers Industry deals channel, wholesalers, brokers, vendors, Research Findings, and Conclusion.

Global Gene Therapy Market report goals to convey a 360-degree perspective available as far as front line innovation, drivers, limitations, and up and coming patterns with sway examination of these patterns available during the estimate time frame. Further, the Gene Therapy Market report additionally shields vital Chaptericipants profiling with SWOT examination, key advancements of items/administrations from the previous five years.

>Company Profiles <

Novartis, Kite Pharma Inc, GlaxoSmithKline PLC, Spark Therapeutics Inc, Bluebird bio Inc, Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica PLC, NewLink Genetics Corp., Amgen Inc

|Click To get SAMPLE PDF of Gene Therapy Market (Including Full TOC, Table & Figures)

Main Points Covered in the Report:

The total market measurements both as far as revenue and volume.

Complete examination about the Gene Therapy market elements, which incorporates the development factors, restrictions, difficulties, and openings.

Detailed data about the key business players, their essential skills, and the Gene Therapy market share.

Strengths of the purchasers and providers which will help customers for improving their decision-making skills.

The most recent 2020 version of this report reserves all provides to give further remarks on the most recent situations, downturn, and effect of COVID-19 on the whole business. It additionally gives subjective data on when the business can reevaluate the objectives the business is taking to address the circumstance and potential activities.

Note In request to give more precise market conjecture, every one of our reports will be refreshed before conveyance by considering the effect of COVID-19.

Connect with our Analyst to understand the CORONA Virus/COVID-19 impact and be smart in redefining Business Strategies @https://marketresearch.biz/report/gene-therapy-market/covid-19-impact

Gene Therapy Market Segmentation Outlook:

By Vector:Viral vectorRetrovirusesLentivirusesAdenovirusesAdeno Associated VirusHerpes Simplex VirusPoxvirusVaccinia VirusNon-viral vectorNaked/Plasmid VectorsGene GunElectroporationLipofection

By Gene Therapy:AntigenCytokineTumor SuppressorSuicideDeficiencyGrowth factorsReceptorsOther

By Application:Oncological DisordersRare DiseasesCardiovascular DiseasesNeurological DisordersInfectious diseaseOther Diseases

Regions Covered in the Global Gene Therapy Market:

The Middle East and Africa (GCC Countries and Egypt)

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Key Questions Answered

What is the size and CAGR of the worldwide Gene Therapy market?

Which are the main portions of the worldwide Gene Therapy market?

What are the key driving elements of the most productive regional market?

What is the nature of competition in the worldwide Gene Therapy market?

How will the worldwide Gene Therapy market advance in the coming years?

What are the fundamental systems received in the worldwide Gene Therapy market?

The study analyses the accompanying key business aspects:

Analysis on Strategies of Leading Players:Market players can utilize this investigation to increase upper hand over their rivals in the Gene Therapy and Equipment market.

Study on Key Market Trends:This segment of the report offers a more profound investigation of the most recent and future patterns of the Gene Therapy and Equipment market.

Market Forecasts:Buyers of the report will approach exact and approved evaluations of the absolute market size as far as worth and volume. The report likewise gives utilization, creation, deals, and different gauges for the Gene Therapy and Equipment market.

Regional Growth Analysis:All significant areas and nations have been canvassed in the report. The local examination will help market players to take advantage of unexplored local markets, get ready explicit procedures for target districts, and think about the development of every single provincial market.

Segmental Analysis:The report gives exact and solid figures of the piece of the pie of significant sections of the Gene Therapy and Equipment market. Market members can utilize this examination to make key interests in key development pockets of the Gene Therapy and Equipment market.

Major Points From TOC:

Chapter One:Overview of Gene Therapy

Chapter Two:Global Gene Therapy Competition Exploration by Top Players

Chapter Three:Top Players Profiles

Chapter Four:Gene Therapy Market Size by Type and Application

Chapter Five:United States Gene Therapy Development Status and Outlook

Chapter Six:EU Gene Therapy Market Development Status and Outlook

Chapter Seven:Japan Gene Therapy Market Status and Outlook

Chapter Eight:China Gene Therapy Market Development Status and Outlook

Chapter Nine:India Gene Therapy Market Outlook

Chapter Ten:Southeast Asia Gene Therapy Market viewpoint

Chapter Eleven:Market Forecast by Type and Application

Chapter Twelve:Gene Therapy Industry Dynamics

Chapter Thirteen:Market Effect Factors Analysis

Chapter Fourteen:Conclusion

....For Detailed InformationClick Here For Complete TOC

A Brief Of The Market Division:

According to the product type, the Gene Therapy market is ordered into In-house, Outsource, Hotels and Small Caterers. In addition, the market share overall industry of each and every item alongside the anticipated valuation is referenced in the report.

Realities identified with the items business value, development rate over the timespan, just as income is available in the report.

Discussing applications, the Gene Therapy market is partitioned into Economy Class, Business Class and First Class. The market share of each product application in tandem with the revenue that every single application may register is present in the report.

Factors And Difficulties Depicted In The Report:

Data about the drivers influencing the commercialization size of the Gene Therapy market just as their effect on the income chart of this vertical is available in the report.

Most recent patterns driving the Gene Therapy market alongside the difficulties in the industry is included in the report.

Marketing Strategies In The Report:

A few strategies that are actualized by the investors with respect to the item showcasing is given in the report.

According to the report, brief with respect to the business channels picked by the organizations are available in the report.

Sellers of these items couple with the brief of clients for the equivalent is referenced in the report.

Investigation Of The Competitors In The Business:

A diagram of the producers presents in the Gene Therapy market containing with as far as possible just as deals zone is associated with the report.

Subtleties of each competitor comprising of organization profile just as their scope of products depicted is initiated in the report.

Information identified with the product deals, income age, value models just as gross edges is portrayed in the report.

The report also speaks about several other information such as evaluation of the competitive landscape, information identified with the market concentration rate and concentration ratio in the upcoming years.

|Have Any Query Or Specific Requirement? Click Here!

MarketResearch.Biz Contact Details:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

More here:
Industry Survey [2020]: Gene Therapy Market Lucrative Growth Analysis [PDF] By 2029 (Cover COVID-19 PANDENIC IMPACT by MarketResearch.biz) - News...

SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and SmartPharm Therapeutics, Inc. (SmartPharm) announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics.

The platform in synergy with Sorrentos industry-leading fully human G-MAB antibody library has the potential to be the engine for the next-generation, cost-effective in vivo production of antibody therapeutics in patients. By encoding the antibody sequence into a plasmid, a single injection into someones muscle could potentially lead the person to make their own antibodies in vivo for months, instead of relying on repeat administrations of an externally manufactured antibody.

We are very encouraged by the preclinical data generated thus far by our STI-2020dna plasmid candidate against COVID-19, said Henry Ji, Ph.D., CEO of Sorrento Therapeutics. But beyond STI-2020dna the integration of the plasmid DNA technology with our existing antibody products has the potential to make antibody therapy much more accessible and affordable for patients, and is applicable to a multitude of indications ranging from cancer to infectious diseases.

The current SmartPharm R&D and senior management team will remain in place and is expected to integrate into the Sorrento research, development, and corporate infrastructure.

The merger was completed on September 1, 2020 and at such time, SmartPharm became a wholly owned subsidiary of Sorrento. The total value of the consideration payable to the holders of capital stock of SmartPharm in the merger was $19.4 million, subject to certain adjustments for net working capital, indebtedness, transaction expenses and cash. Upon completion of the merger, SmartPharm stockholders became entitled to receive an aggregate of approximately 1.76 million shares of Sorrento common stock based on a price per share equal to $10.60.

About SmartPharm Therapeutics

SmartPharm Therapeutics, Inc. is a privately held, development stage biopharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of serious or rare diseases with the vision of creating Biologics from Within. SmartPharm is currently developing a novel pipeline of non-viral, gene-encoded proteins for the treatment of conditions that require biologic therapy such as enzyme replacement and tissue restoration. SmartPharm commenced operations in 2018 and is headquartered in Cambridge, MA, USA. For more information, please visit http://www.smartpharmtx.com.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB library"), clinical stage immuno-cellular therapies ("CAR-T", "DAR-T"), antibody-drug conjugates ("ADCs"), and clinical stage oncolytic virus ("Seprehvir"). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP, ACE-MAB, COVI-MAB, COVI-GUARD, COVI-SHIELD and T-VIVA-19; and diagnostic test solutions, including COVI-TRACK and COVI-TRACE. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido was approved by the FDA on February 28, 2018.

For more information, visit http://www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related toSorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potential effects that the acquisition of SmartPharm may have on Sorrentos business and product candidate pipeline; the data read-outs related to ongoing studies for COVID-19 using antibodies and gene-encoded antibodies; the potency and potential therapeutic capabilities of gene-encoded antibodies and STI-2020dna, and their respective impact on SARS-CoV-2; the expected length of any therapeutic benefit or antiviral protection provided by gene-encoded antibodies and STI-2020dna; the potential administration and applications for a range of disease indications of gene-encoded antibodies and STI-2020dna, alone or in combination; the status of preclinical testing for STI-1499 and STI-2020dna; the therapeutic potential of gene-encoded antibodies, and STI-2020dna for SARS-CoV-2 and COVID-19; the potential costs and cost-effectiveness associated with STI-2020dna and other DNA plasmids; Sorrentos ability to produce antibody candidates against pathogens and cancer cells; Sorrentos ability to transition from product development to full scale manufacturing and commercialization; Sorrentos ability to advance SmartPharms non-viral gene therapy technology and its gene-encoded platform technology; Sorrentos ability to combine SmartPharms technology with Sorrentos technology and manufacturing capabilities; and Sorrentos potential position in the biopharmaceutical industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's technologies and prospects with newly acquired technologies, including the acquisition of SmartPharm and the utilization of SmartPharms Gene-Encoded Therapeutics (GET) platforms for the treatment and prevention of coronavirus infections and other pathogens and cancer cells; risks related to seeking regulatory approvals and conducting clinical trials; the clinical and commercial success of the treatment and prevention of coronavirus infections using gene-encoded antibodies; the viability and success of using gene-encoded antibodies for treatments in anti-viral therapeutic areas, including coronavirus; clinical development risks, including risks in the progress, timing, cost and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that prior study and trial results may not be replicated in future studies and trials; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks related to seeking regulatory approvals and conducting clinical trials; risks of manufacturing drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its strategies; risks related to the global impact of COVID-19 and other risks that are described in Sorrento's most recent periodic reports filed with theSecurities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year endedDecember 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with theSecurities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations

Alexis Nahama, DVM (SVP Corporate Development)Telephone: 1.858.203.4120Email: mediarelations@sorrentotherapeutics.com

Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.G-MAB, COVI-GUARD, COVI-SHIELD, COVIDTRAP, T-VIVA-19, COVI-MAB, ACE-MAB, COVI-TRACK, and COVI-TRACE are trademarks of Sorrento Therapeutics, Inc.

ZTlido is a trademark owned by Scilex Pharmaceuticals Inc.All other trademarks are the property of their respective owners. 2020 Sorrento Therapeutics, Inc. All Rights Reserved.

Follow this link:
Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo...

Shareholders and others will have the opportunity to engage with CEOs from AIM ImmunoTech, Heat Biologics, Avalon GloboCare, Oregenisis, and ImmunoPrecise Antibodies

As the coronavirus (COVID-19) pandemic persists and could possibly strengthen again this fall, dozens of biopharmaceutical companies worldwide are racing to develop life-saving therapies and vaccines.

Five of those companies will participate in the virtual One2One Investor Forum entitled New Approaches to COVID-19: Hidden Breakthroughs to be held on September 10 at 1pm ET.

The virtual panel discussion will include Tom Equels, CEO of AIM ImmunoTech Inc (NYSEAMERICAN:AIM); Jeff Wolf, CEO of Inc (); Dr David Jin, CEO of (); Vered Caplan, CEO of Oregenisis Inc (); and Dr Jennifer Bath, CEO of () (OTCQB:IPATF).

The virtual One2One Investor Forum will be moderated by broadcast journalist Christine Corrado of Proactive Investors. The event, co-sponsored by investorrelations firm Crescendo Communications, is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and management from some of the world's most cutting-edge businesses.

is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine.

The North Carolina-based company heads into the forumjust after releasing some promising preclinical results from a study of a potential vaccine based on its already-developed gp96 platform which is designed to activate immune responses against cancer or pathogenic antigens. The company also just won a second US patent protection for the platform.

Heat said the study found the vaccine significantly increases the frequency of systemic and tissue-specific CD8+ T-cells by conferring cellular immunity thats essential against any viral infection, including SARS-CoV-2, the virus that causes the COVID disease.

Also, the company said the vaccine elicits a robust immune response directed against the Spike protein of SARS-CoV-2, generating both helper CD4+ T-cells that aid in antibody production as well as virus killing cytotoxic CD8+ T cells.

The company said the generation of a durable cellular immune response driven by memory CD8+ T cells also may protect against re-infection. Heat's vaccine is designed to prophylactically "train" the immune system to induce this response in patients, especially in individuals most prone to severe infection such as the elderly, those with comorbidities, or others who are immuno-suppressed.

"We believe that these results are a powerful reinforcement that this platform represents a unique and relevant paradigm for novel vaccine development, capable of inducing cellular immune responses in epithelial tissues such as the lungs, said CEO Wolf in a recent statement

This publication demonstrates the potential utility and versatility of our vaccine platform to address SARS-CoV-2, relevant mutations and other pathogens of interest."

Florida-based AIM ImmunoTech focuseson the research and development of therapeutics to treat immune disorders, viral diseases, and multiple types of cancers.

But it also has developed the drug Ampligen, which the company said decreasedthe infectious viral yield of SARS-CoV-2 by 90% in a recent in vitro model.

"We are pleased with these results, as they establish Ampligen's bio-activity against SARS-CoV-2 as well as support our decision to test Ampligen in humans as an intranasal prophylaxis and early-onset therapy against COVID-19," said CEO Equels in a recent statement.

In conjunction with the Institute for Antiviral Research at Utah State University, the company tested Ampligen and found that a dramatic reduction in viral yield could be achieved at clinically achievable dosage levels. These results support Ampligens goal of developing an intranasal prophylactic approach using Ampligen to prevent the coronavirus. Ampligen has already been tested on the SARS-CoV-1 (SARS) virus, showing antiviral promise.

Also, the company recently signed a trilateral material transfer and research agreement with Japan's National Institute of Infectious Diseases and a Japanese pharmaceutical company to test Ampligen as a potential vaccine adjuvant for COVID-19. Ampligen has been shipped to Japan, to be followed up with an additional shipment.

Furthermore, the company has plans for a Phase 1/2a trial of Ampligen with Roswell Park Comprehensive Cancer Center to commence patient enrollment soon. The trial will examine Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19.

AIM also has the financial runway to advance the development of Ampligen, which is also being studied as an immuno-modulator to treat melanoma, colorectal and ovarian cancers. It amassed $40.3 million as of June 30, nearly 5 times more than the $8.8 million it had at the end of 2019.

Avalon GloboCare, which specializes in developing cell-based technologies to combat cancer, has been marshaling its resources to help fight the pandemic on three fronts: marketing a test kit for a partner company, developing therapeutics to fight cytokine storms (bodys immune attacks its own cells), and creating a vaccine.

The company also has established the Avalon Combat Covid-19 Taskforce to accelerate scientific/clinical development to help combat the Covid-19 pandemic through a strategic combination of therapeutic and vaccine approaches.

Last month, the New Jersey-based company won distribution rights to market Cellex Incs coronavirus antibody-based rapid test. Cellex recently earned Emergency Use Authorization from the US Food and Drug Administration to build and sell the kits. Both are working as well to source manufacturing facilities and to develop next-generation COVID-19 detection kits.

For COVID therapeutics, Avalon is working with the Massachusetts Institute of Technologyto co-develop a therapeutic platform against the cytokine storm, which causes lung damage. Cytokines are small protein molecules in the body required to regulate and maintain proper physiological functions, but when released in excess, the cytokine stormdamages vital tissues and organs.

Avalons AVA-Trap therapeutic program is currently entering animal model testing followed by expedited clinical studies with the goal of providing an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms.

In early September, the company launched its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform as a potential therapy for COVID-19 and bone marrow transplant-related complications of acute graft versus host disease (aGVHD).

Avalon also recently formed a partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna to co-develop a surface-layer vaccine for SARS-CoV-2.

The vaccine is expected to both decrease the severity of a SARS-CoV-2 infection preventing the more severe respiratory inflammation and organ damage and building immunity against the virus. Avalon plans to complete the proof-of-concept pre-clinical studies in 2020, followed by a first-in-human clinical study of this candidate vaccine during 2021.

Inc (), which develops cell and gene therapy platforms, is collaborating with Holdings Inc () to develop and potentially obtain FDA marketing approval of Ranpirnase to treat patients suffering from severe acute respiratory syndrome.

Maryland-based recently acquired the assets of Tamir Biotechnology Inc, including Ranpirnase, a broad spectrum anti-viral agent. Ranpirnase catalyzes the degradation of RNA, and mediates several essential biological activities, including the regulation of cell proliferation, maturation, differentiation, and cell death.

Over 1,000 patients have been dosed with Ranpirnase in previous cancer/mesothelioma clinical trials.Ranpirnase has already demonstrated a strong safety and tolerability profile.Ranpirnase also has shown preclinical antiviral activity in serious viral diseases, such as cytomegalovirus (CMV), influenza, HIV, Ebola, and SARS.

has conducted in vitro studies of Ranpirnase at the University of Tennessee Health Sciences Center Regional Biocontainment Laboratory and George Mason University National Center for Biodefense and Infectious Diseases against the SARS CoV-2 virus. The in vitro studies demonstrated that Ranpirnase was significantly effective in killing the virus with an eight-fold average decrease in the number of plaque-forming units when cultures with Ranpirnase were compared to the controls treated with a placebo.

Based on these initial pre-clinical results, a pre-IND meeting request to fast track Ranpirnase for the treatment of SARS-COV-2 has been submitted by to the FDA.

"We believe this platform could address a significant need in the market and we look forward to leveraging expertise in the development and clinical trial oversight, as well as relationships with government agencies, to possibly accelerate the development of Ranpirnase and its use as a potential treatment of patients with SARS-COV-2,said CEO Caplan recently.

() (OTCQB:IPATF) has developed a broad portfolio of therapeutic antibodies that bind to multiple regions of the SARS-CoV-2 spike protein.

In July, the Vancouver company announced that its DeepDisplay phage technology confirmedthat a subset of six of these antibodies that were analyzed in combinationresultedin near-complete neutralization of SARS-CoV-2 pseudovirus infection.

As we characterize IPAs approximately seventy-five functional lead candidates it is clear that our extensive program has generated therapeutics with broadly diverse profiles, providing substantial opportunities for multi-epitope targeted strategies, said CEOBath in a recent statement.

After selecting approximately sixteen hundred antibodies with the most desirable binding profiles to various spike protein formats, we down-selected our leads based on very specific criteria, all of which are key in our ongoing determination of ideal candidates.

The company continues to further analyze multiplesubsets of antibodies, including neutralizing antibodies demonstrated to bind to the S1 and S2 domains of the SARS-CoV-2 spike protein. Furthermore, the company has begun steps for the expression of the lead antibodies for pre-clinical and clinical manufacturing.

For ImmunoPrecise, PolyTope is the name of its scientifically rigorous and comprehensive approach employed in its anti-COVID-19 programs, as company scientists lead extensive efforts toward the development of effective coronavirus preventions and therapies.

The company noted that its lead antibodies against COVID-19 (or SARS-CoV-2) have not yet been studied in human clinical trials and, as a result, ImmunoPrecise is not making any express or implied claims that its products have been proven to have the ability to eliminate, cure or contain both the virus and disease at this time.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Read more:
Biopharmaceuticals battling COVID-19 pandemic to connect with investors via Proactive One2One Investor Forum on September 10 - Proactive Investors USA...

Bleeding disorders usually include symptoms in which delay in the blood clotting process can be observed. Two main types of blood disorders include von Willebrand disease and hemophilia, both of which are hereditary in nature. Von Willbrand is one of the most common congenital bleeding disorders in humans, caused as a result of deficiency of Von Willebrand factor (VWF) which assists in clot clotting process.

There are three types of Von Willebrand disorders classified on the basis of level of VWF synthesis. Von Willebrand disorders occurrence is almost equal in both sexes, and affects about 1% of the general population according to the Centers for Disease Control and Prevention (CDC). The most common complications of the disorder include heavy menstrual bleeding, excessive gum bleeding and abnormal bleeding after minor injuries. Hemophilia, on the other hand, is a disorder in which clotting factors essential for clotting phenomenon are inadequate or absent. In the U.S. about 400 newborns suffer from hemophilia every year according to statistics published by the CDC. The two main types of hemophilia are hemophilia A with deficiency of clotting factor VIII and hemophilia B with deficiency of clotting factor IX. The National Heart, Lung and Blood Institute, U.S. details that approximately 7 out of 10 individuals who suffer from hemophilia A have severe form of the disorder.

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12218

Global Bleeding Disorder Therapeutics market Witness Most Promising Rise in Demand

Geographically, global Bleeding Disorder Therapeuticsmarket is segmented into North America, Europe, Asia Pacific and Rest of the world (RoW) regions. Currently, North America is leading the global Bleeding Disorder Therapeutics(CSCs) market and is followed by Europe. Factors such as highly developed research infrastructure, well defined regulatory norms, availability of research funds, availability of skilled research and healthcare professionals and supportive economy are driving the North American Bleeding Disorder Therapeuticsmarket towards growth. Asia Pacific is lucrative market for cancer stem cells. Governments in the Asia Pacific countries mainly, India and China are taking initiative to boost the healthcare and biotechnology industry in the respective countries and thus, research and development activities in these countries are swiftly increasing.

Request for Analysis of COVID19 Impact on Bleeding Disorder Therapeutics Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=12218

The study offers an in-depth assessment of various customers journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

Key Players of Bleeding Disorder Therapeutics Market Report:

Companies are also trying to discover gene therapy which can cure the disorder. Some of the players conducting lineal trials are Biogen Idec, Novo Nordisk, Bayer Healthcare, Xenetic Biosciences, Cangene Corporation, CSL Behring, Alnylam and Pfizer. The global bleeding disorder therapeutics market is highly competitive and fragmented. Technological advances will expand the boundaries of the market by adding new products. In 2014, Baxter International, Inc. agreed to acquire Chatham Therapeutics. The acquisition will give Baxter Chathams developmental gene therapy program which is directed toward of treatment of hemophilia.

Buy Bleeding Disorder Therapeutics Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=12218&ltype=S

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

View post:
Bleeding Disorder Therapeutics Market: Report Analysis Global Market Revenue and Share by Manufacturers Boosting the Healthcare Industry Worldwide -...

Investment Thesis

Relay Therapeutics share price performance since IPO

(Source: TradingView)

Investors looking to place a bet on the next big biotech trend may want to take a close look at Relay Therapeutics (RLAY), a novel drug discovery startup with a strong management team, access to one of the world's most powerful supercomputers, and nearly $1 billion in funding, having completed the third-largest biotech IPO of all time in mid-July.

Relay's upsized IPO raised $400 million after the company sold 20 million shares for $20 - above the marketed range of $18-19 - to complement the $520 million it had already raised across 3 private funding rounds from backers including the SoftBank Vision Fund, Google Ventures, the Biotechnology Value Fund, and Third Rock Ventures. Shares traded up by 75% on the first day of trading, closing at $44, but have declined slightly and are currently available at a price of $35.3.

Relay's high-profile backers are supporting a brains trust comprising computational chemists, biophysicists, data scientists and drug development experts with access to the Anton 2 supercomputer developed by D.E. Shaw Research, whose founder, David E. Shaw, is also one of Relay's founders, alongside Matthew Jacobson, a faculty member in the Department of Pharmaceutical Chemistry at the University of California, Dorothee Kern, Professor of Biochemistry at Brandeis University, and Mark Murcko, a Senior Lecturer at MIT and formerly chief technology officer at Vertex Pharmaceuticals (VRTX).

The company has developed a proprietary platform, Dynamo, which it is using to pioneer a novel drug discovery paradigm based on generating insights into protein motion, a concept the company refers to as Motion Based Drug Design ("MBDD"), leveraging techniques including crystallography, cryoEM, molecular simulations and machine learning.

These techniques allow Relay to gain access to harder to reach targets with small molecules, such as the allosteric sites on proteins, which are responsible for regulating many of a protein's activities. The company's initial focus is on oncology, specifically the treatment of solid tumours, although Relay is confident its techniques may be adapted to treat genetic and other diseases.

Relay's pipeline is early-stage, and consists of 3 candidates, designed to inhibit protein tyrosine phosphatase SHP2, tyrosine kinase receptor FGFR2 and cellular signalling pathway regulator PI3K, respectively, with SHP2 inhibitor RLY-1971 currently undergoing a phase 1 dose escalation study.

Although it is hard to assign a target price to such an early-stage biotech, there are reasons to believe that an investment into Relay at this time may result in gains over the long term.

Thanks to advances in technology, allosteric drug discovery looks set to become an increasingly important and potentially lucrative market within the pharma industry.

Traditionally, drug developers target the more accessible active site of proteins, known as the orthosteric site, but most of the "low-hanging fruit" targets have already been claimed, and treatments developed by early-stage biotechs and Big Pharma, meaning drug developers are having to widen their search and look deeper and with more penetration at alternative targets.

For example, in July 2018, biotech Revolution Medicines (RVMD) licensed an allosteric SHP2 inhibitor to Novartis (NVS) for a $50 million upfront fee, plus up to $500 million of milestone payments, and in 2016, Gilead (GILD) paid $400 million up front and agreed to milestone payments worth $800 million to acquire Nimbus Therapeutics' allosteric Acetyl-CoA Carboxylase (ACC) inhibitor program.

Research suggests that the allosteric sites on proteins offer drug developers the chance to identify and develop safer and more effective treatments, but these treatments are also more expensive to develop. What may give Relay a significant head start is its powerful technology (as described in the video below), which can be leveraged to identify targets with a theoretically higher chance of treatment success, and its advantageous funding position.

With one candidate already in the clinic and two set to follow, investors ought to benefit from regular news flow in the shape of data readouts, investigational new drug ("IND") and biologics license applications ("BLAs"), and potentially, lucrative development and commercial agreements with major pharmas, whilst the field's high barriers of entry ought to keep the competition at bay.

In the rest of this article, I will take a closer look at Relay's team, candidates, strategy and addressable market. Backing Relay may require a leap of faith and patience, but the opportunity to acquire shares at a discount to their IPO price may not exist for long, whilst the financial strength of Relay's backers limits the downside case, in my view, although the company's high cash burn of $84 million in FY19 and $26 million in the first 3 months of 2020 should be noted.

Relay Therapeutics is based in Cambridge, Massachusetts, and was spun out of the biotech accelerator Third Rock Ventures in 2015. Third Rock has backed numerous Nasdaq-listed biotechs, such as bluebird bio (BLUE), Editas Medicine (EDIT), Global Blood Therapeutics (GBT), Sage Therapeutics (SAGE) and Constellation Pharmaceuticals (CNST), with decidedly mixed success to date.

Listed Third Rock Ventures seeded companies share price performance over 5-year period

(Source: TradingView)

I would put the disappointments down to the experimental nature of many of the companies. Sage, for example, looked set to commercialise a novel CNS treatment until a high-profile trial failure decimated its share price, while bluebird bio operates in the gene therapy space, which has failed to make the impact to date that many experts felt it would.

It is still early days for all of these companies, however, and we can also see from the chart above that all of these stocks are highly volatile, providing plenty of opportunities for risk-on investors who time the market right to make strong short- to medium-term gains. Relay is likely to reflect the same trend.

Relay has moved quickly to build a strong management team which is led by President and CEO Sanjiv J Patel, who joined from Allergan, where he was Chief Strategy Officer. Don Bergstrom, ex Merck, Sanofi and Mersana Therapeutics, where he specialised in antibody-drug conjugates, leads Relay's R&D, whilst Pat Walters, who spent 20 years at Vertex Pharmaceuticals, heads up Relay's Computation & Informatics division. Relay's General Counsel is Brian Adams, who joined from Keryx Pharmaceuticals.

The remainder of the senior management team have decades of biotech experience and an impressive array of skill sets, however I highlight the 4 staff above, as I see leadership, the drug-development / clinical trial process, computation and legal as perhaps the most important elements of Relay's strategy.

In order to succeed, the company will need to leverage its technology and the skill of its team to identify and purchase optimised compounds, and ensure the clinical trial process runs smoothly and that excellent relationships with the FDA and other authorities are maintained, whilst protecting its IP, particularly as and when drugs begin to approach the commercialisation stage.

Relay Therapeutics Presentation at AWS Events

(Source: YouTube)

The above video provides an insight into how Relay uses its Dynamo technology to search for and purchase the compounds it then uses to drug proteins.

Initially, the company uses a variety of different techniques to try to model the motion of proteins, attempting to create a more rounded and dynamic set of insights into its activity than can be achieved using the more traditional method of static imaging. In a recent interview, Relay founder Dorothee Kern explained:

In textbooks, the drug simply binds the protein, and then, game over, but in reality, binding is a series of conformational changes, with the compound changing the energy landscape of a protein. The idea is that different compounds can cause different changes. One molecule might shift the protein in a direction that shuts down the active site, while another might turn it on.

The company tries to look at both wild-type and mutant forms of the protein and uses, for example, room temperature X-ray crystallography and Cryo-EM, and the Anton Supercomputer to create a "movie" of how the protein might behave over time, based on calculating the forces between millions of atoms over a minute (slices of 2.5 x10-15 seconds). Compared to other drug developers, Relay says in its IPO prospectus that its simulations are based on a time scale that is 100x longer.

A 10 microsecond simulation of a 1 million atom benchmark protein (satellite tobacco mosaic virus), which requires one day of processing on the Anton 2, would require 271 days on conventional hardware (Nvidia V100). Quote from IPO prospectus.

Relay virtual screening process

(Source: Relay Therapeutics presentation at AWS Events)

Having identified a target protein, Relay then screens tens of billions of possible compounds, which are evaluated and scored according to their chances of being successful, based on characteristics such as potency, binding capabilities, bioavailability and selectivity. The company then purchases a selection of the top-ranked compounds from a "synthesis on demand" provider and proceeds to evaluate them in vitro.

Relay's platform compared to conventional drug discovery programs

(Source: IPO prospectus)

Relay has now developed 2 ready-for-the-clinic, plus 1 experimental candidate. Since the company's process is repeatable, its technology ought to improve over time as in vitro studies and human trials progress, which could lead to the development of drug franchises across a number of indications.

This gives Relay different options. It is sufficiently well-funded to progress candidates independently, which would pay off if one of its candidates is approved and starts to generate blockbuster (+$1 billion per annum) sales, but this is a risky and expensive process that could leave the company empty-handed, having burned through hundreds of millions of dollars.

The alternative option is to use the model favoured by many drug developers, which is to secure commercial partnerships with larger pharmas, who fund drug development programmes in part or often in full after a certain stage of progress has been reached, in return for the rights to market and sell the drug, with the drug-developer receiving a percentage - usually in the low double digits - of all sales, as well as milestone payments when certain key development stages are reached, i.e., a pivotal trial, submission of IND, etc.

The downsides here are the smaller revenues the company will generate (~90% less than when going it alone), and when a pharma signs an agreement in principle to partner on, for e.g., 3 candidates, but opts against taking up the option on candidates 2 and 3 when they are developed, which leaves the developer with nothing to show for its early-stage development work.

A good example of these types of companies and arrangements can be found in the field of RNAi-based treatments, for e.g., Dicerna Pharmaceuticals (DRNA), which has co-development agreements in place with Novo Nordisk (NVO), Roche (OTCQX:RHHBY), Eli Lilly (LLY), Boehringer Ingelheim and Alexion (ALXN), or Arrowhead (ARWR), which works alongside Janssen, a subsidiary of Johnson & Johnson (JNJ) and Amgen (AMGN).

Relay current candidates

(Source: Company website)

Relay's current candidates all address solid tumours and inhibit the signalling pathways of specific proteins to prevent the proliferation of cancerous cells, meaning they may be adapted to treat a wide range of cancers, including many of the most prevalent, for e.g., lung, breast, colorectal, liver and kidney.

RLY-1971 is the most advanced candidate, and like the Revolution candidate I mentioned earlier that was acquired by Novartis, it is an allosteric inhibitor of the protein tyrosine phosphatase ("SHP2"), which helps cancerous cells to spread by relaying messages downstream from receptor tyrosine kinases ("RTKs"). To quote founder Kern again:

You can view an allosteric binder as a knob where you can dial in how much activation or inhibition you want. Nature has built these allosteric networks in for regulation. Lets take advantage of them.

RLY-1971 has only made it as far as a phase 1 dose escalation study with advanced or metastatic solid tumors, enrolling 52 participants, with the primary endpoint being to establish a recommended for a phase 2 trial, but the secondary outcome measures - plasma concentration levels, objective response rate ("ORR") and Disease Control Rate ("DCR") - and other outcome measures, including duration of response ("DOR"), progression free survival ("PFS") and tumor mutations, are highly intriguing and offer plenty of share price catalysts if early signs suggest RLY-1971 has an impactful effect on these measures.

SHP2 monotherapy and combination therapy addressable patient populations

(Source: Relay IPO prospectus)

RLY-4008 is an oral, small molecule, selective inhibitor of FGFR2, which is one of four members of the FGFR family. Whilst it's known that targeting FGFR2 in patients with intrahepatic cholangiocarcinoma has demonstrated clinical proof of concept, developers have only been able to produce non-selective, pan-FGFR inhibitors to date, which cause collateral damage by also inhibiting FGFR1, which causes hyperphosphatemia.

Prevalence of hyperphosphatemia in non-selective FGFR inhibitors

(Source: Relay IPO prospectus)

Relay has used its computational models to discover motion-based differences between the two protein types, making it easier to actively target FGFR2 without inhibiting the other family members. This is a great example of how the company's processing power can make the difference when targeting the more complex allosteric site over the orthosteric.

Finally, RLY-PI3K1047 is another signalling pathway regulator, targeting PI3K, which research has indicated may be the most frequently mutated kinase in cancer. Using Dynamo, Relay has been able to model the first full-length protein structure of PI3K, which is important, since prior attempts to inhibit the protein's functions have usually resulted in intolerable levels of toxicity. If the protein can be better understood and mapped, it may unlock the secret to a more effective and safer anti-tumor treatment.

Market value indication of PI3K inhibition

(Source: Relay IPO prospectus)

Relay says it is already leveraging Dynamo to produce 3 more precision oncology programs, and with most of the pieces in place - management, funding, technology and access to funding - required to operate a company successfully, there seems to be little standing in the way of the company rolling out many more candidates over the coming years.

Although there will be volatility in the short term, patience may be the key to holding Relay stock. The company's strategy is predicated upon developing computational analysis of proteins and their functions to new and higher levels of complexity, and generating superior insights, hence it does not want to get pressured into releasing candidates before they are ready purely in order to satisfy the market's demand.

Relay's cash burn - currently at ~$100 million per annum (based on Q120 spend of $26 million) is high and likely to increase substantially as the number of candidates increases and clinical trials begin in earnest. Having listed, fresh funding is likely to come from, and therefore dilute, investors once the current ~$800 million or so of funding is exhausted. This should not happen for at least 18 months at the earliest, however.

It can be very tricky for a layperson investor to get to grips with different drug developers' technologies and decide which are likely to succeed and which aren't, but it is possible (although not always advisable) to look at who else is invested in the company's success.

Relay Chairman and founding investor Alexis Borisy was the founder of Foundation Medicine, acquired by Roche for $5 billion. Another board member, Linda A Hill, is Professor of Business Administration at the Harvard Business School, whilst another, Douglas Ingram, is President and CEO of Sarepta Therapeutics, a commercial-stage biotech that has grown its share price by 344% over the past 5 years.

I would advise against an investment in Relay if you are not won over by the technology side of the business, but despite the fact it is still relatively unproven, and it may be years or even decades away from reaching its peak (based on the ongoing struggles of, for e.g., CAR-T therapy, gene therapy, and RNAi to make a significant impact on the global oncology or other disease markets), it seems a reasonable thesis to me that examining the activities of proteins in more detail can ultimately result in the development of superior treatments.

Since there ought to be no shortage of short-term catalysts as Relay and Dynamo start to reach full-throttle, and based on the overall performance of other Third Rock Venture seeded companies (which suggests a strong culture of good management, oversight and financial planning), I would consider Relay to be a reasonable investment opportunity at a price of $35.3, and as any experienced biotech investor will know, a positive set of data that suggests above standard-of-care efficacy can easily move a stock price by anything from 10% - >100%.

Longer term, Relay appears (in my view) to have an above average chance of graduating to a mid-stage biotech with commercialised products, which gives the current share price plenty of upside potential, in my view.

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth.

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in RLAY over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Excerpt from:
Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy - Seeking Alpha

Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers

Roots Analysis is pleased to announce the publication of its recent study, titled, Cell Therapy Manufacturing Market (3rd Edition), 2019 2030.

The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing. It focuses on both contract manufacturers, as well as developers with in-house manufacturing facilities, offering in-depth analyses of the various business entities that are engaged in this domain, across different global regions. Amongst other elements, the report includes:

Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Type of therapy

Source of cells

Scale of operation

Purpose of manufacturing

Key geographical regions

Key companies covered in the report

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

View post:
Cell Therapy Manufacturing Market is estimated to reach close to USD 11 Billion by 2030 - Scientect